Journal of Cellular Biochemistry Supplement 24:32–91 (1996)

NCI-Navy Medical Oncology Branch Cell Line Data Base

Ruby M. Phelps, Bruce E. Johnson, Daniel C. Ihde, Adi F. Gazdar, David P. Carbone, Patrick R. McClintock R. Ilona Linnoila, Mary J. Matthews, Paul A. Bunn, Jr., Desmond Carney, John D. Minna, and James L. Mulshine

National Cancer Institute-Navy Medical Oncology Branch, National Naval Medical Center, Bethesda, Maryland 20897 (R.M.P., B.E.J., D.C.I., A.F.G., R.I.L., D.P.C., M.J.M., P.A.B., D.C., J.D.M., J.L.M.); American Type Culture Collection, 12301 Parklawn Dr., Rockville, MD 20852 (P.R.M.)

Abstract The cell line data base described in this paper includes both clinical information about the patients from whom the cell lines were derived and information about the in vitro analyses performed of the cell lines. The cell line data base has evolved as a part of a systematic effort by a research group at the NCI since 1976 to generate human cell lines as biological tools to study cancer and other diseases. The cell lines were generated from clinical specimens obtained as part of a series of Institutional Review Board-approved clinical protocols. The preponderance of the data is on lung cancer cell lines, though a broad range of other cancers are represented. A bank of over 300 human cell lines including cancer cell and in some instances autologous B-lymphoblastoid cells from the NCI-VA and NCI-Navy Medical Oncology Branch are reposited at the American Type Culture Collection. The cell lines are available for the research community. The entire data base is available on the American Type Culture Collection Web Site (WWW:http://www.atcc.org/). © 1996 Wiley-Liss, Inc.*

Key words: cell lines, clinical correlation, in vitro data, polymorphic markers, lung cancer

This cell line data base was created in response to ongoing requests from scientists and clinical investigators for clinical data which could be correlated with the results of various laboratory studies performed using the human tumor cell line bank. This cell line bank was begun at the National Cancer Institute (NCI)-Veteran's Administration (VA) Branch in August 1976 and was continued when the NCI moved its affiliation to the Bethesda Naval Hospital in July 1981 establishing the NCI-Navy Medical Oncology Branch.

There are over 300 human tumor (HUT) cell lines, lymphoblastoid (BL) lines, and lines derived from human tumor passaged in nude mice (NUT). The majority of cell lines were established from small cell and non-small cell lung cancer tissue. The remainder were from colon, GI, T-cell lymphomas, breast primary tumors, metastatic sites, or myeloma.

MATERIALS AND METHODS

The tissue for attempted cell line establishment was typically obtained as a part of ongoing clinical trials which allowed for study of tumor specimens in the laboratory and provided for patient treatment. In that setting, there were extensive patient data available. Tissue was also obtained as a result of a tissue procurement protocol where a patient signed a consent form to allow their tissue to be studied, but further follow-up information was not prospectively collected and treatment of that patient was not encompassed by the consent. In those cases, treatment and follow-up information may be limited or non-existent. There are also a limited number of patients for whom normal lymphocytes were obtained in addition to tissue for cell line growth. A number of these lines were immortalized with EB (Epstein-Barr) viral co-infection. In some of these cases, a cell line was not established but information obtained on the patient at that time is still contained in the data base.

CELL LINE AND CLINICAL CORRELATION

Tissue for cell line growth has been obtained from patients at various stages of illness, that is, at diagnosis, at relapse, at the time of surgery for curative or palliative reasons, or at the end stage of disease. To enable those trying to draw meaningful clinical correlations from data generated with these cell lines, as much information

Received January 19, 1996.

Address reprints requests to Dr. J. Mulshine, Biomarkers and Prevention Research Branch, Division of Clinical Sciences, National Cancer Institute, KWC 300, 9610 Medical Center Dr., Rockville, MD 20850-3300 or MulshineJ@BPRB.NCI.NIH.GOV

© 1996 Wiley-Liss, Inc. *This article is a US Government work and, as such, is in the public domain in the United States of America.

as possible has been obtained about the natural history of disease for each patient, including such items as date of diagnosis, first treatment date, etc.

SOURCES OF THE DATA

Although the cell line initiative was begun in 1976, the computerized cell line data base was not begun until June 1989. Consequently, most data collection for the older cell lines was retrospective, and information was not always available or complete. The primary source for the data was the patient oncology clinic chart. If the chart was not available, data was obtained using computerized data sets of protocol study results and information contained in various other files (pathology consultation sheets, records of conferences where the patient case may have been presented, notebooks containing consultation reports, etc.). Data collection, other than survival follow-up for protocol patients, ended in December of 1991 when the personnel responsible for the initiative transferred out of the National Cancer Institute, Navy-Medical Oncology Branch. Other key individuals in this effort have also moved to other facilities. Therefore this project will end with the publication of the Cell Line Supplement and the deposition of the cell lines in the American Type Culture Collection (ATCC), Rockville, MD.

DATA ACCURACY

The cell line data base was created and maintained by one individual (R.M.P.). Reports of data contained in the cell line data base have been distributed periodically to all associated investigators for review and concurrence. The existence of a cell line in the laboratory has been confirmed with associated researchers maintaining the cultures (H.O., E.R.). Although there are a few internal computer edits (such as invalid date checking), most data verification has been done manually although extensively. Data have been checked by comparing the logic of each field with other fields, for example, *diagnosis* date must come before treatment start date, death dates should be after diagnosis dates, etc. Data have also been compared with computerized protocol patients data sets which have been thoroughly reviewed before statistical analysis. Response to treatment information has been compared to the protocol data base. Staging has been based on information available in the chart, with final assessment by the principal investigator for all protocol patients. No information is

TABLE I. Critical Abbreviations Used

Diagnosis codes		Response codes		Source of specimen	
AD	Adenocarcinoma	CR	Complete remission	AD	Adrenal
AL	Acute leukemia	PR	Partial remission	AS	Ascites
BA	Bronchoalveolar	SD	Stable disease	BM	Bone marrow
CA	Carcinoid	NC	No change	BO	Bone
ES	Esthesioneuroblastoma	ND	No disease (resected)	BR	Brain
LC	Large cell	NE	Not evaluable	CE	Cervix
LY	T-cell lymphoma	NR	No response	CO	Colon
ME	Mesothelioma	ID	Induction death	LI	Liver
MI	Mixed	PD	Progressive disease	LN	Lymph node
MY	Myeloma	MR	Minimal response	LU	Lung
NE	Neuroendocrine			ME	Mediastinal mass
NS	Not specified			OT	Other
SC	Small cell			PE	Pleural effusion
SQ	Squamous cell			ST	Soft tissue

Performance status (ECOG)	Race	Growth medium	
0	W White	A4 ACL4[2,3]	R5 RPMI 1640, 5% FBS
1	B Black	HI-0 HITES, NO SERUM[4]	R10 RPMI 1640, 10% FBS
2	H Hispanic	HI-2 HITES, 2% FBS	RSP RPMI 1640 w/special additives
3	O Oriental	HI-5 HITES, 5% FBS	IMDM (Iscove's modification of Dulbecco's medium)
4		HI-10 HITES, 10% FBS	F12K10 Ham's F12K

assumed. If data are not available the fields are left blank or are "unknown," depending on circumstances explained below.

DESCRIPTION OF THE DATA BASE

The data base was developed using DB3+ and is compatible with DB4 and with any other data base programs which will read DBase files, including Foxpro.

The key fields in the data base are ID and NCI_H or NCI_BL number. The ID number is a number assigned to each patient. A patient may have more than one cell line but only one ID. This will enable the researcher to match all cell lines for a particular patient if desired. The data base at the end of this article is in NCI_H number order which corresponds to the sequence in which tumor arrived in the tumor biology lab. Confidential information such as patient name and social security number, although contained in our unit's master file, are not in the published data base. The ID number was assigned to compensate for this. The ATCC# is the catalog number provided by the American Type Culture Collection. An asterisk (*) in this field indicates a difficult line for cell line banking. The code "U" or "Unk" is used for "unknown" in cases where information is available on a patient but that particular item was not obtained (such as smoking history) and further searching of patient records would be unlikely to provide the needed item. In cases where there is no information available, due to a lack of chart or other resource, fields are left blank.

The age was computed from the cell line date and the date of birth. Cell line date is the date the tissue was received in the laboratory. Race (R), performance status (PS), specimen (SOS) codes, and diagnostic (DX) codes are contained in Table I. Stage (ST) is either L for limited, E for extensive (as in small cell lung cancer), or 1, 2, 3, 4 A and B, for non-small cell lung and other cancers. In the few cases of colon cancer, stage is listed as A, B, C, or D in the Comments section, when known. In the cases where the primary cancer was other than lung, the primary is indicated in the Comments section, or is obvious by the histological type (i.e., myeloma). The disease stage is that obtained at the time of diagnosis and may not describe the extent of tumor at the time the cells for tissue culture were obtained. Prior therapy (PRRX), prior radiation therapy (PRT), prior chemotherapy (PRCT), and treatment after (RXAF) fields provide simple yes or

TABLE II. NCI-VA and NCI-Navy Protocols*

Protocol	Drugs	Disease
$SC4_5$	CMC/VAP, VP16, Ifosfamide	Small cell lung cancer (extensive)
771_5	CMC/VAP, VP16, ifosfamide	Small cell lung cancer (extensive)
784_6	Adriamycin, mitomycin-C	Non-small cell lung cancer
773_7	CAPO	Small cell lung cancer (extensive)
$803/818_8$	CMC/VAP	Small cell lung cancer (extensive)
$774/813_9$	CMC/VAP (+) or (−) chest radiation	Small cell lung cancer (limited)
$8315_{10,11}$	VP16/cis-platinum or IVBR	Non-small cell lung cancer
8313_{12}	VP16/cis-platinum high VS standard dose, VAC or IVBR at 12 weeks[a]	Small cell lung cancer (extensive)
835_{13}	CBDCA (phase 2)	Small cell and non-small cell lung cancer
853_{14}	Dihydrolenperone (DHLP) (phase 1)	Non-small cell lung cancer
854_{15}	Monoclonal antibody 2A11 (phase 1/2)	Small cell lung cancer
855_{16}	VP-16/Cis-platinum and chest radiotherapy; VAC or IVBR at 12 weeks[a]	Small cell lung cancer (limited)

*CMC/VAP: cyclophosphamide, methotrexate, CCNU/vincristine, adriamycin, procarbazine; CAPO: cyclophosphamide, adriamycin, cis-platinum, vincristine; VAC: vincristine, adriamycin, cyclophosphamide.

[a]In vitro best regimen combinations tested (IVBR). *Small cell lung cancer:* Cyclophosphamide, adriamycin, cis-platinum; cyclophosphamide, cis-platinum, VP-16; adriamycin, cis-platinum, VP-16; cyclophosphamide, adriamycin, methotrexate; cyclophosphamide, adriamycin, VP-16; cyclophosphamide, methotrexate, VP-16; adriamycin, methotrexate, VP-16; cyclophosphamide, adriamycin, vincristine; cyclophosphamide, methotrexate, vincristine; cyclophosphamide, methotrexate, CCNU; adriamycin, vincristine, VP-16; vincristine, methotrexate, VP-16; cyclophosphamide, vincristine, CCNU. *Non-small cell lung cancer:* cis-platinum, VP-16; cyclophosphamide, adriamycin, methotrexate, procarbazine; cyclophosphamide, adriamycin, cisplat.; mitomycin-C, velban, cis-platinum; vindesine, cis-platinum; fluoruracil, vincristine, mitomycin-C; cyclophosphamide, methotrexate, CCNU; fluoruracil, adriamycin, mitomycin-C.

no answers as to whether the patient received radiation and/or chemotherapy before and/or after the tissue for cell line establishment was obtained. First treatment date is the date the patient was first treated for his or her cancer. Details are contained under the heading Drugs, but may also include any surgical resection, radiation therapy or other information which may have an impact on cell line growth (such as prior therapy for another cancer). Response (RS) is the overall best response to therapy (codes are contained in Table I). Other Rx contains information on later treatment received after failure of initial therapy or at time of relapse. The response (RES) to later therapy is also provided. Protocol is the NCI-VA or NCI-Navy protocol on which the patient received treatment. A general description of these protocols is provided in Table II. If the stated protocol is "none," the patient received treatment at NCI but was not placed on a protocol. If the protocol field is left blank, it is not known whether the patient was treated on a study. Because a few of the cell lines were established from tissue sent from other institutions, it is possible the patient was treated on a study elsewhere.

Some abbreviations of drugs as well as other abbreviations used in the data base are contained in Table III.

Death dates and diagnosis dates are provided when known. Smoking (SMK) is either Y (yes), N (no), or U (unknown). Smoking pack years (PCKYRS) are computed by multiplying the number of packs per day × the number of years smoked. The comments area lists any additional information, unusual histology or primary site, and follow-up information on living patients. Growth media (MEDIUM) descriptions are provided in Table I. L-Dopa decarboxylase (DDC)[1] levels on pure cell lines growing vigorously (*not* fresh tumor), are listed for some lines. Small cell sub-type (SCSUBTYPE) obtained on *fresh specimen* at diagnosis is listed by number: 21, 22, 21/22, or 22/40. Small cell sub-type on *cell lines* (CLINESUB) is either C for Classic or V for Variant.

The two parts of the cell line data base are presented as Table IV and Table V respectively. In Table IV, the clinical information and data about the cell culture conditions are listed. In Table V, a range of in vitro data about the cell lines compiled largely by one of the authors (DPC) is presented.

TABLE III. Other Abbreviations Used

ADJ	Adjuvant
A, ADRIA	Adriamycin
ASP	L-Asparaginase
BL	Bleomycin
DAUN	Daunorubicin
D/C	Discharged
HYDROXY	Hydroxyurea
IORT	Intraoperative radiotherapy
IT	Intrathecal
IVBR	In-vitro best regimen
MMC	Mitomycin-C
NED	No evidence of disease
PCI	Prophylactic cranial irradiation
PD	Progressive disease
PENTA	Pentamadine
PL, PLAT	Cis-platinum
RT	Radiation therapy
SC	Supraclavicular nodes
TAMOX	Tamoxifen
VEL	Velban
VINB	Vinblastine
VIND	Vindesine

DISCUSSION

We encourage the investigator, in trying to correlate laboratory findings with clinical and prognostic information (particularly as regards patient survival), to develop an unbiased methodical approach in choosing the appropriate parameters and the requisite cell line numbers (the advice of a statistician may be useful in this determination) to avoid the potential for misinterpretation of study results.

ACKNOWLEDGMENTS

The authors acknowledge the contributions of the house staff, clinical care nurses, research nurses, and faculty of Naval Hospital Bethesda, especially the cardiothoracic surgery, pulmonary, and pathology services, as well as the patients and their family members who made this resource possible. Other major participants in the cell line acquisition project: Bimal Ghosh, MD, Anita Johnston-Early, RN, Sylvia Stephenson, Margaret Edison, RN, John Nesbitt, MD, Herbert Oie, PhD, Harvey Pass, MD, John Phares, MD, Edward Russell, Robert Wagner, MD, Thomas Walsh, MD, Edward Woods, MD.

REFERENCES

1. Gazdar A, Helman L, Israel M, et al (1988): Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078–4082.

2. Brower M, Carney D, Oie H, et al (1986): Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 46:798–806.
3. Gazdar A, Oie H (1986): Correspondence regarding growth of cell lines and clinical specimens of human non-small cell lung lung cancer in a serum free defined medium [letter]. Cancer Res 46:6011.
4. Simms E, Gazdar A, Abrams P, Minna J (1980): Growth of human small cell (oat cell) carcinoma of the lung in serum-free growth factor-supplemented medium. Cancer Res 40:4356–4363.
5. Cohen M, Ihde D, Bunn P, et al (1979): Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 63:163–170.
6. Doyle L, Ihde D, Carney D, Bunn P (1984): Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Severe pulmonary toxicity from q 3 weekly mitomycin C. Am J Clin Oncol 7:719–724.
7. Brower M, Ihde D, Johnston-Early A, Bunn P, et al (1983): Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. Am J Med 75:993–1000.
8. Ihde D, Deisseroth A, Lichter A, et al (1986): Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 4:1443–1454.
9. Bunn P, Lichter A, Makuch R, et al (1987): Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: A prospective randomized trial. Ann Intern Med 106:655–662.
10. Stevenson H, Gazdar A, Phelps R, et al (1990): Tumor cell lines established in vitro: An independent prognostic factor for survival in non-small cell lung cancer. Ann Intern Med 113:764–770.
11. Shaw G, Gazdar A, Phelps R, et al (1994): Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 53:5181–5187.
12. Ihde D, Mulshine J, Kramer B, et al (1994): Randomized comparison of high-dose and standard-dose etoposide (VP16) and cisplatin in patients with disseminated small cell lung cancer (SCLC). J Clin Oncol 12:2022–2034.
13. Dmitrovsky E, Seifter E, Gazdar A, Tsai C, et al (1990): A phase II trial of carboplatin (CBDCA) in small-cell and non-small cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol 13:285–289.
14. Johnson B, Parker R, Strong J, Tsai C, et al (1990): Completion of the dihydrolenperone (DHLP) phase 1 trial. A novel compound with in vitro activity against lung cancer. Proc Am Soc Clin Oncol 9:230.
15. Mulshine J, Avis I, Carrasquillo J, et al (1990): Phase 1 study of an anti gastrin releasing peptide (GRP) monoclonal antibody in patients with lung cancer. Proc Am Soc Clin Oncol 9:230.
16. Johnson B, Salem C, Nesbitt J, et al (1991): Limited (LTD) stage small cell lung cancer (SCLC) treated with concurrent BID chest radiotherapy (RT) and etoposide/cisplatin (VP/PL) followed by chemotherapy (CT) selected by in vitro drug sensitivity testing (DST). Proc Am Soc Clin Oncol 10:240, 1991.

ADDENDUM: OBTAINING THE NCI-NAVY MEDICAL ONCOLOGY DATABASE FILE

The information in Tables IV and V is available online through the ATCC via their Web Site (WWW:http://www.atcc.org/) and these files can be downloaded via Netscape. For those investigators without easy access to Internet, if a formatted disk is provided to Dr. Pat McClintock at ATCC Cell Culture Department, 12301 Parklawn Drive, Rockville, MD 20852, a copy of the database can be returned on the disk as a delimited ASCII file. Please make sure to include specific shipping address information along with your request. For those Internet users without Netscape, the database can also be downloaded from the ATCC FTP server (ftp.atcc.org/pub/nci-lines). If user demand is heavy, ATCC may be required to charge a handling fee to defray the cost of this service.

LEGEND TO TABLE IV

A	NCI cell line number
B	ATCC cell line number
C	cell line identifier number
D	patient age
E	date of birth
F	sex
G	race
H	performance status (ECOG criteria)
I	cell line initiation date
J	source of specimen
K	diagnosis
L	stage at initial evaluation
M	first treatment date
N	prior treatment (any)
O	prior radiation therapy
P	prior chemotherapy
Q	second-line treatment (any)
R	specific initial drug/radiation therapy (relapse treatment)
S	response to treatment
T	NCI protocol number
U	NCI-cell line number
V	dopa decarboxylase level for the cell line
W	second-line treatment course start date
X	second-line treatment
Y	comments
Z	response to second-line treatment
AA	death date
BB	initial diagnosis date
CC	smoker
DD	number of pack years of cigarette
EE	tissue culture media used for growing the cell line
FF	small cell lung cancer histologic subtype/classic or variant morphology

TABLE IV. (Part 1). NCI-Navy Medical Oncology Branch Cell Line Data Base: Clinical and Cell Culture Information

NCIH NCIBL	ATCC #	ID	Age	DOB	Sex	R	PS	Cell line DT	SOS	DX	ST	1ST RX date	PRRX	PRT	PRCT	RXAF	First RX (RX for Relapse)	RS	PRO
0023	CRL 5800	134	51	12/24/24	M	B	U	08/31/76	LU	AD	UNK	08/31/76	N	N	N	Y	CCNU/HYDROXY RT bone	PD	
0028	CRL 5820	270	48	09/28/27	M	W	1	09/22/76	PE	ME	4	10/15/76	N	N	N	Y	VCR, CTX, 5FU; RT mediast, ADRIA	PD	
0060	CRL 5821	138	51	08/17/25	F	W	2	06/09/77	PE	SC	E	11/12/76	Y	Y	Y	N	CMC/VAP VP16/IFOS chest RT	PR	SC4
0064	*	269	54	10/14/22	M	B	1	08/04/77	LN	SC	E	02/04/77	Y	Y	Y	N	CMC/VAP VP16/IFO chest RT	PR	771
0069	HTB 119	149	55	09/10/22	M	W	3	09/16/77	PE	SC	E	05/13/76	Y	Y	Y	N	CMC/VAP VP16/IFOS, PCI	CR	SC4
0078	TIB 161	301	53		M	W		12/13/77	LN	LY	4B		Y	N	Y	Y	Oral steroids, chemo		
0082	HTB 175	083	41	11/17/36	M	W	1	01/06/78	PE	SC	E	08/17/77	Y	Y	Y	N	CMC/VAP, VP16, RT chest	CR	None
N0087	CRL 5822	305			M			07/16/76	LI	AD									
0102	TIB 162	302	29		M	W		05/18/78	LN	LY	4B		N	N	N	Y	Topical mustard, MTX		
0123		199	67	03/26/12	M	B	2	03/07/80	LN	SC	E	02/27/80	Y	N	Y	N	CMC/VAP	PR	
0125	CRL 5801	105	61	01/19/17	M	B	U	10/26/78	ST	MI	4	11/09/78	N	N	N	Y	ADRIA/MMC chest RT PL, PENTA	PD	784
0128 B0128	HTB 120 CRL 5947	185	59	12/16/18	M	B	2	12/05/78	PE	SC	L	02/22/78	Y	Y	Y	N	CMC/VAP chest RT	PR	774
0146	HTB 173	156	60	05/07/18	M	W	1	03/08/79	BM	SC	L	04/24/78	Y	N	Y	Y	CMC/VAP	PR	774
0157	CRL 5802	248	59	05/07/20	M	W	U	05/08/79	PE	SQ	3B	05/22/79	N	N	N	Y	ADRIA/MMC	PD	784
N0177		138	52	08/17/25	F	W	1	08/15/78	PE	SC	E	11/12/76	Y	Y	Y	N	CMC/VAP, VP16/IFOS	PR	771
0182	*	119	53	05/18/25	F	W	2	09/04/79	LN	SC	E	06/02/78	Y	Y	Y	Y	CAPO; RT chest/head; PL	PR	773
0187	CRL 5804	073	47	10/19/31	M	W	2	10/02/79	PE	SC	E	10/05/79	N	N	N	Y	CAPO; IT MTX; RT brain	PR	773
0196	CRL 5823	075	68	04/08/10	M	W	2	10/31/79	PE	SC	E	12/16/77	Y	Y	Y	Y	CAPO, PCI	CR	773
0209 B0209	HTB 172 CRL 5948	262	55		M	W	4	12/19/79	BM	SC	E		N	N	N	N	None		
0211	CRL 5824	123	50	12/15/27	F	W	2	01/03/80	BM	SC	E	12/20/78	Y	Y	Y	Y	CMC/VAP chest RT, PLAT	PR	None
0220	CRL 5825	048	51	02/19/29	M	B	1	02/29/80	PE	SC	E	02/28/80	N	N	N	Y	CMC	NR	773
0226	CRL 5826	118			M			03/12/80	PE	SQ,ME			N	N	N	N			
0249	CRL 5827	040			M			06/09/80	BM	SC			Y	N	Y	N	MTX 1977 for LC		
0250	CRL 5828	202	34	04/20/46	M	B	3	06/17/80	BR	SC	E	06/25/80	N	N	N	Y	CMC/VAP brain RT	PR	803
0285	CRL 5829	159	35	07/28/45	M	B	3	11/17/80	LN	SC	E	11/20/80	N	N	N	Y	CMC/VAP brain RT	NR	818
0289 B0289		059	45	07/24/35	F	W	1	11/21/80	PE	SC	E	11/21/80	N	N	N	Y	CMC, brain RT	ID	818
0290		089			M			11/19/80	PE	ME									
0292	CRL 1848	233	32	11/30/47	F	B	U	11/25/80	LN	CA	4	12/15/80	N	N	N	Y	CMC; RT bone	PD	
0295	CRL 10296	002							AD										
0298		215	41	11/14/37	M	W	1	12/05/80	PE	SC	E	06/01/79	Y	Y	Y	N	CAPO; PCI; CMC, VIND	PR	773
0322	CRL 5806	237	52	02/20/29	M	W	0	02/24/81	ST	BA	4	08/24/78	Y	N	Y	N	ADJ CMC, VAP for resected SCCL	CR	
0324		251	62	11/15/18	M	B	4	03/02/81	PE	AD	4	03/15/81	N	N	N	Y	1 Cycle drugs, UNK	PD	

Part 1. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH NCIBL	ATCC #	ID	Age	DOB	Sex	R	PS	Cell line DT	SOS	DX	ST	1ST RX date	PRRX	PRT	PRCT	RXAF	Drugs	RS	PRO
0345	HTB 180	231	64	07/20/16	M	W	1	06/18/81	BO	SC	L	11/02/79	Y	Y	Y	Y	CMC/VAP, RT chest, PCI	CR	813
0358	CRL 5807	080			M			08/18/81	LU	BA									
0360		030			M			08/25/81	OT	SC									
0369		220	51	02/10/30	M	W	2	09/24/81	LN	SC	E	05/19/81	Y	N	Y	Y	CMC/VAP	PR	818
0372		038	59	12/02/21	M	W	3	10/17/81	BM	SC	E	06/29/81	Y	N	Y	N	CMC/VAP	PR	
0378	CRL 5808	211	66	02/23/15	F	W	1	11/13/81	PE	SC	E	04/24/81	Y	Y	Y	N	CMC/VAP RT neck, shoulder	PR	818
0379		211	66	02/23/15	F	W	1	11/13/81	PE	SC	E	04/24/81	Y	Y	Y	N	CMC/VAP	PR	818
N0390		112	48	12/15/29	M	B	1	02/02/79	LN	SC	E	02/13/79	N	N	N	Y	VAC; VP16 chest RT	PR	None
N0408		267	55	01/16/24	M	B	1	03/27/79	LI	SC	E	03/30/79	N	N	N	Y	VAC; PCI chest RT	PR	None
N0417	CRL 5809	303			F	O		03/15/80	LU	SC									
0432		029			M			05/05/82	ST	SC									
0433		029			M			05/05/82	ST	SC									
0441	HTB 174	268	33	06/23/48	M		4	05/25/82	PC	AD	3A	05/28/82	N	N	N	Y	RT pericard; mediast, hilum		
0446	HTB 171	235	62	05/20/20	M	W	1	05/24/82	PE	SC	L	12/10/81	Y	N	Y	N	CMC/VAP	PR	813
0449		223	70	06/05/12	F	W	2	06/08/82	BM	SC	E	10/22/81	Y	Y	Y	Y	CMC/VAP, PCI	CR	818
0450		223	70	06/05/12	F	W	2	06/08/82	LN	SC	E	10/22/81	Y	Y	Y	Y	CMC/VAP, PCI	CR	818
0460	HTB 177	086			M			07/23/82	PE	LC									
0462		186	40	12/10/41	M	W	3	08/04/82	BM,R	SC	E	08/05/82	N	N	N	Y	CMC	PD	
0463		186	40	12/10/41	M	W	3	08/04/82	BM,L	SC	E	08/05/82	N	N	N	Y	CMC	PD	
0478		028			F			08/23/82	LU	SC									
0498	CCL 254	208	56		M	W		09/22/82	LI	AD									
0508	CCL 253	151			M			10/04/82											
0510	HTB 184	051	55	06/15/27	M	W	1	10/06/82	AD	SC	E	08/01/80	Y	Y	Y	Y	Brain RT, CMC/VAP Adrenalectomy	SD	None
0513	CRL 5830	200	64	09/13/18	M	W	1	10/13/82	PE	ME	3A	12/15/82	N	N	N	Y	Bleomycin adria	PD	None
0520	HTB 182	127			M			11/09/82	LU	SQ									
0522	CRL 5810	131	58	01/20/24	M	W	0	11/18/82	LU	AD	2	12/20/82	N	N	N	Y	Resect RT chest PCI bone RT	ND	8315
0524	CRL 5831	158	63	01/01/19	M	W	1	11/22/82	LN	SC	L	03/05/82	Y	N	Y	Y	CMC/VAP	PR	813
0526	CRL 5811	136	55	08/07/27	M	W	1	11/22/82	BM	SC	E	11/24/82	N	N	N	Y	CMC/VAP	PD	818
0548	CCL 249	084	52	06/06/30	M	W	1	01/20/83	CO	AD	4								
0568		226	71	01/27/12	M	W	2	02/28/83	LN	SC	L	02/28/83	N	N	N	Y	CMC	ID	813
0571		307	53	03/09/29	M		1	01/25/83	PE	SC	L	01/23/82	Y	Y	Y	N	CMC/VAP chest RT	PR	813
0578		168	54	02/26/27	M	W	1	03/15/83	LN	SC	E	09/23/81	Y	N	Y	Y	CMC/VAP	CR	
0580		242	51	04/19/30	M	W	1	03/04/83	BM	SC	E	02/02/82	Y	Y	Y	Y	VAC chest RT, (VP16 > PD)	PR	
N0592	CRL 5832	040			M			06/09/80	BM	SC									
0596	HTB 178	110	70	04/23/13	M	W	1	05/06/83	ST	MI	3A	06/23/82	Y	Y	N	N	Resect. chest and chest wall RT		
0606		020	37	12/04/45	M	W	1	06/24/83	PE	SC	E	06/21/82	Y	N	Y	N	CMC/VAP	PR	818
0615		238	56	11/16/25	M	W	3	08/01/83	LN	SC	E		N	N	N	Y	Brain RT		

0618		046	48	09/07/34	M	W	1	07/19/83	BM	SC	E	07/23/83	N	N	N	Y	CMC/VAP chest RT	PR	818
0620		145	61	03/19/22	M	W	1	08/17/83	BM	SC	L	09/27/82	Y	Y	Y	N	CMC/VAP chest RT brain RT for Mets	CR	813
0630	CRL 5833	194			M			09/13/83	LI										
0640	*	085	60	10/07/23	F	W	1	10/13/83	LU	LC	2	10/13/83	N	N	N	Y	Excision L lung; POST OP, RT		
0647	CRL 5834	212	56	03/18/27	M	W	1	10/24/83	PE	MI	3A	05/10/83	Y	Y	N	N	CURAT., RT chest, bone,	PD	
0650	CRL 5835	072			M			10/31/83	LN										
0660	CRL 5813	170	63	12/31/19	M	W	4	11/17/83	LN	SC	E	11/18/83	N	N	N	Y	VP/PLAT	ID	8313
0661	HTB 183	162	43	05/02/40	M	W	1	11/21/83	LN	LC	3B	08/24/83	Y	Y	Y	Y	PL/VINBL, chest, SC node RT	MR	835
0676	HTB 179	042	63	10/13/20	M	W	1	12/29/83	PE	AD	4	06/07/83	Y	N	Y	Y	CTX, ADRIA, MTX, PRO; 1/84 VEL, (PL > PD)	PR	835
0678		096	69	10/18/14	M	W	3	01/09/84	PE	SC	E	01/10/84	N	N	N	Y	VP/PLAT	PR	8313
0679		183	65	02/17/18	M	W	1	01/11/84	LU	MI	2	01/30/84	N	N	N	Y	CMC/VAP, ADJUV	PD	
0684		222						01/16/84	LI										
0689		100	53	06/19/30	M	W	1	01/26/84	PE	SC	E	02/12/83	Y	Y	Y	N	CMC/VAP, PCI	CR	818
N0691		308	54	07/03/26	F		2	03/13/81	PE	SC	L	04/18/80	Y	Y	Y	N	CMC/VAP chest RT	CR	813
0711	CRL 5836	210	49	02/14/34	M	W	1	02/10/84	BM	SC	E	02/11/84	N	N	N	Y	VP/PL	PD	8313
0716	CCL 251	193			M			04/06/84	AS										
0719	CRL 5837	256	55	12/30/28	F	W	1	04/10/84	BM	SC	E	04/12/84	N	N	N	Y	VP/PL; VAC-PR brain RT, 11/85	CR	8313
0720	CRL 5838	259			M			04/11/84	LU	CA									
0726		239	57	01/23/27	F	W	2	04/24/84	PE	AD	3A	10/16/83	Y	Y	Y	Y	MELPH, RT pelvis R ovary, chest RT	PD	8315
0727	CRL 5815	178	65	03/25/19	F	W	0	04/24/84	LU	CA	3A	04/24/84	N	N	N	Y	R upper lobect; chest RT		8315
0735	*	107	58	08/27/25	F	W	1	05/24/84	LI	SC	E	11/17/83	Y	N	Y	Y	VP/PL, VAC; 6/84 VP/PL, MTX	PR	8313
0738	CRL 5839	160	67	11/18/16	F	W	2	06/01/84	LI	SC	E	06/01/84	N	N	N	Y	VP/PL	PR	8313
0740	CRL 5840	191	63	08/30/20	M	W	1	06/06/84	LN	SC	E	06/15/84	N	N	N	Y	VP/PL, VAC; 12/85 RT chest spine	PR	8313
0742		169	58		M	W		06/15/84	CO										
0747	CCL 252	146			M			07/02/84	LN										
0748	CRL 5841	147	62	06/28/22	M	B	1	07/03/84	LN	SC	E	09/10/83	Y	Y	Y	Y	CMC/VAP, PCI	CR	818
0768		224			F			08/13/84	CO										
0774	CRL 5842	184	43	07/15/41	M	W	1	07/25/84	ST	SC	E	07/28/84	N	N	N	Y	VP/PL	PR	8313
0792		147	62	06/28/22	M	B	1	08/29/84	PE	SC	E	09/10/83	Y	Y	Y	Y	CMC/VAP, PCI	CR	818
0810	CRL 5816	061	51	01/17/33	M	B	0	09/14/84	LU	LC	2	09/14/84	N	N	N	Y	L LLobe, Resect; chest RT		8315
0820	HTB 181	126	50	07/21/34	M	W	3	09/26/84	LN	BA	4	05/11/84	Y	N	Y	N	5FU, ADR, MMC, PL	PD	None
0835	CRL 5843	066	48		F	B	0	10/15/84	LU	CA									
0838	CRL 5844	130	59	03/13/25	M	W	1	10/16/84	LN	AD	3B	10/19/84	N	N	N	Y	Chest RT		8315
0841	CRL 5845	114	51	06/12/33	M	W	0	10/17/84	LN	SC	L	04/17/84	Y	Y	Y	N	CMC/VAP chest and SC RT; VP/PL	NR	813
0847	CRL 5846	090	63	03/04/21	M	W	1	10/18/84	PE	SC	L	08/29/84	Y	Y	Y	N	CMC/VAP heart RT	PD	813
0854	CRL 5847	065	75	06/02/09	M	W	2	10/22/84	CO	AD	4	10/22/84	N	N	N	N	Hemicolectomy for Obst		
0862	CRL 5848	258	60	02/17/24	F	W	0	11/02/84	BM	SC	E	02/09/84	Y	N	Y	Y	VP/PL	CR	8313

Part 1. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH NCIBL	ATCC #	ID	Age	DOB	Sex	R	PS	Cell line DT	SOS	DX	ST	1ST RX date	PRRX	PRT	PRCT	RXAF	Drugs	RS	PRO
0865	CRL 5849	246	54	10/05/30	F	W	1	11/08/84	PE	SC	L	05/13/83	Y	Y	Y	Y	CMC/VAP chest RT, PCI	CR	813
0889	CRL 5817	050	69	03/26/15	F	W	1	07/13/84	LN	SC	E	07/14/84	N	N	N	Y	VP/PL	PR	8313
0890		091	59	02/02/25	F	W	0	03/27/84	BM	SC	E	03/30/84	N	N	N	Y	VP/PL; PCI, PD 1/85, NO RX	CR	8313
0920	CRL 5850	216	43	02/09/41	M	W	1	12/20/84	LN	AD	4	02/15/85	Y	Y	N	Y	Chest RT		8315
0929	CRL 5851	003			F			12/28/84		MY									
0930		265	55	07/24/29	F	W	2	01/02/85	LN	SC	L	05/15/84	Y	N	Y	Y	VAC > PR (CMC > PD)	PR	835
0958		140	54		M	W		02/15/85	LI										
0962		244			M			02/15/85	LN	SC									
0969	CRL 5852	081	66	10/28/18	M	W	1	02/13/85	PE	AD	4	03/06/85	N	N	N	Y	CAP (IVBR); Brain RT	SD	8315
1008		076	53	10/05/31	M	W	1	03/20/85	BM	SC	L	01/28/84	Y	Y	Y	N	CMC/VAP chest RT; VP/PL-PD	PR	813
1011		005			M			03/20/85		ES									
1045	*	098	43	11/08/41	M	W	1	05/08/85	BM	SC	E	02/20/85	Y	Y	Y	Y	VP/PL spine RT	PD	8313
1048	CRL 5853	052			F			04/15/85	PE	SC									
1059	CRL 5854	172	59	12/15/25	F	W	2	05/21/85	OT	SC	E	05/30/85	N	N	N	Y	CMC-CR, VP/PL-CR	CR	854
1061		218	35	02/13/50	F	W	4	05/23/85	BM	SC	E	05/25/85	N	N	N	Y	VP/PL; CT, ADRIA, VP (IVBR); RT chest bone	PR	8313
1062		218	35	02/13/50	F	W	4	05/23/85	BM	SC	E	05/25/85	N	N	N	Y	VP/PL; CT, ADRIA, PL RT bone and chest	PR	8313
1086	*	097	70	05/27/15	F	W	1	06/11/85	PE	SC	L	08/20/84	Y	Y	Y	N	CMC/VAP chest RT	CR	813
1092	CRL 5855	255	67	03/27/18	M	W	3	06/21/85	BM	SC	E	06/24/85	N	N	N	Y	VP/PL PL, CT, VP-PR-IVBR	PD	8313
1105	CRL 5856	247	73	05/09/12	M	W	2	07/08/85	LN	SC	E	07/13/85	N	N	N	Y	VP/PL, CAV (IVBR)-PR brain RT	PR	8313
1112		004								MY									
1155	CRL 5818	257	36	10/17/48	M	W	2	08/30/85	LN	LC	3A	09/16/85	N	N	N	Y	Chest RT		8315
1173	CRL 5957	023	63	08/29/22	F	W	1	09/18/85	ST	SC	E	09/24/85	N	N	N	Y	VP/PL brain RT	CR	8313
1184	CRL 5858	053	42	01/25/43	M	W	0	09/15/85	LN	SC	L	09/26/85	N	N	N	Y	CMC/VAP chest RT	CR	813
B1184	CRL 5949																		
1185	*	177	44	01/25/41	F	W	1	09/24/85	ST	SC	L	03/06/85	Y	Y	Y	Y	CMC/VAP chest RT, PCI	CR	813
1238	CRL 5859	058	64	07/01/21	M	W	3	11/06/85	BM	SC	E	11/15/85	N	N	N	Y	VP/PL; VAC	PR	8313
1264	CRL 5860	213	54	04/02/31	M	B	1	11/27/85	LU	MI	3A	11/27/85	N	N	N	Y	Resect R lung; IORT; chest RT	CR	8315
1284	CRL 5861	266	75	06/13/10	M	W	2	12/26/85	BM	SC	E	12/28/85	N	N	N	Y	VP/PL	ID	8313
1299	CRL 5803	232	43	08/30/42	M	W	1	01/14/86	LN	LC	3A	10/04/85	Y	Y	N	Y	Partial R lung Resect; chest, SC node RT	PD	8315
1304	CRL 5862	174	56	07/26/29	F	W	4	01/21/86	PE	SC	E	10/25/85	Y	N	Y	Y	VP/PL; VAC, RT brain, METS	PR	8313
1315		033	50	06/24/35	M	W	1	02/03/86	ME	MI	L	02/19/86	N	N	N	Y	VP/PL, VAC-PR, (DHLP-PD)	PR	853
1330		227			M			02/14/86	CO								Chest RT		8315
1334	CRL 5863	203	56	02/15/30	M	W	4	02/23/86	OT	LC	3A	03/15/85	Y	Y	N	Y	VP/PL; CAV-PR, (IVBR); chest RT	PR	8313
1339	*	067	49	05/23/36	F	W	1	02/27/86	PE	SC	E	03/04/86	N	N	N	Y			
B1339	CRL 5950																		

1341	CRL 5864	152			F			02/28/86	CE	SC									
1355	CRL 5865	122	53	11/06/32	M	W	3	03/11/86	PE	AD	4	02/13/86	Y	Y	N	N	Spine RT		8315
1373	CRL 5866	264	56	04/15/29	M	B	1	03/20/86	OT	AD	3A	10/18/84	Y	Y	Y	N	R lower lobe Resect; RT chest, brain	ND	8315
1378		101	69	03/08/17	M	W		03/24/86	LU	SQ	3A	05/01/86	N	N	N	Y	Chest RT patient refused to finish		
1385	CRL 5867	056	49	04/19/36	F	B	1	04/11/86	LN	SQ	3A	04/28/86	N	N	N	Y	Mediast RT		8315
1387		045	40	09/10/45	M	W	3	04/21/86	LI	AD	2	01/02/85	Y	Y	N	N	Hemicolectomy; RT	CR	None
1395 B1395	CRL 5868 CRL 5957	254	55	08/01/30	F	W	1	04/24/86	LU	AD	2	04/25/86	N	N	N	Y	L lower lobect., 5/87 RT brain, MET		8315
1404	CRL 5819	129	48	11/20/37	M	W	1	05/12/86	LN	BA	4	05/21/86	N	N	N	Y	VP/PL, DHLP-PD chest RT	PD	8315
1412		093			M			05/20/86	LI	AD									
1417	CRL 5869	092	61	11/03/24	F	W	1	05/22/86	LU	SC	E	06/03/86	N	N	N	Y	VP/PL, CAV-PR (IVBR); brain RT	PR	8313
1435	CRL 5870	181	35		F			06/19/86	LU										
1436	CRL 5871	139	39	11/18/46	M	W	1	06/20/86	LN	SC	E	06/23/86	N	N	N	Y	VP/PL, VP, AD, PL (IVBR)-PR	PR	8313
1437 B1437	CRL 5872 CRL 5958	148	60	04/10/26	M	W	1	06/24/86	PE	AD	1	05/31/83	N	N	N	N	L upper lobect.		8315
1440		027						06/26/86	CO										
1447		261	40		M			07/09/86	LN	AD									
1450 B1450	* CRL 5951	104	64	05/01/22	M	W	4	07/14/86	BM,R	SC	E	07/16/86	N	N	N	Y	VP/PL	ID	8313
1451		104	64	05/01/22	M	W	4	07/14/86	BM,L	SC	E	07/16/86	N	N	N	Y	VP/PL	ID	8313
1466	*	044	73	08/23/12	M	W	1	08/13/86	PE	AD	3A	03/31/86	Y	N	Y	N	VP/PL	NC	8315
— B1474		273	63	05/12/23	M	W	1	09/20/86	PE	AD	3B	09/25/86	N	N	N	Y	CMC; no cell line	PD	8315
— B1489		041	57	05/13/29	M	W	1	09/11/86	LU	BA	1	09/11/86	N	N	N	N	L upper lobect.; no cell line		8315
1498	*	068	61	04/01/25	F	W	2	09/23/86	PE	BA	4	09/25/86	N	N	N	Y	VP/PL	NC	8315
1512		144			M			10/07/86	PE										
1514 B1514	CRL 5873 CRL 5952	241	56	06/11/30	F	W	1	10/08/86	BM	SC	E	10/16/86	N	N	N	Y	VP/PL; RT bone, brain	CR	8313
1522	CRL 5874	206	53	09/22/33	M	W	1	10/16/86	PE	SC	E	06/12/86	Y	Y	Y	Y	VP/PL; VAC-PR, brain RT	PR	8313
— B1533		217	74	02/24/12	F	W	1	10/31/86	LU	AD	3A	10/31/86	N	N	N	Y	R upper lobect; chest RT no cell line		
1548		171			M			11/18/86	LU										
1563	CRL 5875	125			M			12/12/86	LU										
1568	CRL 5876	074	48	05/11/38	F	W	1	12/22/86	LN	AD	4	01/15/87	N	N	N	Y	VP/PL brain RT	PD	8315
1570		150	48	06/09/38	M	W	1	12/23/86	LU	LC	3A	11/15/86	Y	N	Y	Y	VP/PL	PR	
1573	CRL 5877	116	35	08/21/51	F	W	2	12/29/86	ST	AD	4	12/15/86	Y	Y	N	Y	Brain RT		8315
1581	CRL 5878	263	44	10/01/42	M	W	2	01/29/87	LU	LC	4	01/29/87	N	N	N	Y	L lung resect.		8315
— B1582		271	23	02/15/64	M	W		03/26/87	BM	AL		02/13/87	Y	N	Y	Y	VCR, ADR, CTX, IT, MTX, ASP, MMC-IVBR	NR	
1592		175	59		F	W	1	02/27/87	LN	AD	3B	03/24/87	N	N	N	Y	5FU/ADR/MMC-IVBR	PD	8315
— B1601		128	57	03/15/29	M	W	1	03/09/87	PE	AD	3B	05/15/87	N	N	N	Y	CAP no cell line	PD	8315

Part 1. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH NCIBL	ATCC #	ID	Age	DOB	Sex	R	PS	Cell line DT	SOS	DX	ST	1ST RX date	PRRX	PRT	PRCT	RXAF	Drugs	RS	PRO
1607 B1607	CRL 5953	069	54	05/02/32	M	W	1	03/18/87	LN	SC	E	03/25/87	N	N	N	Y	VP/PL; VAC-PR brain RT	PR	8313
1608		135			F			03/28/87	LU										
— B1612		047	75	07/02/11	M	W	1	03/27/87	LN	AD	3A	04/08/87	N	N	N	Y	RT lung Mediast; no cell line		8315
1618	CRL 5879	180	55	02/13/32	F	W	1	04/10/87	BM	SC	E	04/16/87	N	N	N	Y	VP/PL; CVP-NR (IVBR)	NC	8313
1622	CRL 5880	180	55	02/13/32	F	W	1	04/16/87	LN	SC	E	04/16/87	N	N	N	Y	VP/PL; CVP-NR (IVBR)	NC	8313
1623	CRL 5881	197	58	06/11/28	M	W	1	04/17/87	LN	AD	3B	06/04/87	N	N	N	Y	Chest RT	PD	8315
1628	*	077	50	07/22/36	M	W	1	04/20/87	LN	SC	L	04/20/87	N	N	N	Y	VP/PL; chest RT; VAC-PD (IVBR)	PR	855
— B1632		021			F												No cell line		
1648 B1648	CRL 5882 CRL 5954	176	39	08/04/47	M	B	0	05/22/87	LN	AD	3A	06/08/87	N	N	N	Y	VP/PL Resect; VP-16	CR	8315
1650	CRL 5883	249	27	07/28/59	M	W	1	05/28/87	PE	BA	3B	06/11/87	N	N	N	Y	CT, AD, PL (IVBR)	PD	8315
1651	CRL 5884	108	71		M		0	05/28/87	LU										
1652		132			M			05/28/87	LI										
1666	CRL 5885	057	50	05/05/37	F	W	2	06/23/87	PE	BA	3?	12/15/86	Y	Y	N	N	Chest RT		
1670		024			F			06/29/87	LI										
1672 B1672	CRL 5886 CRL 5959	207	58	03/08/29	M	W	1	07/01/87	LU	SC	L	07/17/87	N	N	N	Y	VP/PL, chest RT	CR	855
1688 B1688	CCL 257	143	50	01/25/37	M	W	1	07/16/87	LI	SC	E	07/17/87	N	N	N	Y	VP/PL; brain RT; VAC-NR	PD	8313
— B1690		062			F												No cell line		
1693	CRL 5887	078	55	11/15/31	F	W	2	07/23/87	LN	AD	3B	08/17/87	N	N	N	Y	VP/PL chest RT	PR	8315
1694	CRL 5888	109	61	10/18/25	M	W	2	07/23/87	AS	SC	E		N	N	N	N			
— B1700		031	51	03/02/36	M	B		08/15/87	LU	AD	1	08/15/87	N	N	N	N	R upper lobe resection, no cell line		
1703	CRL 5889	219	54	10/28/32	M	W	1	08/05/87	LU	SQ	1	08/05/87	N	N	N	Y	Resect.		
1710	*	113	48	11/21/38	M	W	1	08/13/87	LU	BA	4	11/10/87	N	N	N	Y	DHLP	PD	853
1717	CRL 5890	124	66	04/14/21	M	W		08/25/87	LU	SQ									
1725		190	54	06/25/33	F	W	1	09/04/87	LN	LC	4	09/30/87	N	N	N	Y	Chest and brain RT	PD	
1734	CRL 5891	240			F		0	09/21/87	LU										
— B1740		209			M												No cell line		
1755	CRL 5892	043	65	02/25/22	F	W	1	10/21/87	LI	AD	4	09/29/87	N	N	N	Y	Brain RT		8315
1769		055	59	12/25/27	M	W	1	11/10/87	LN	SC	L	11/12/87	N	N	N	Y	VP/PL and RT > PR; CT/VC/CCNU (IVBR)	CR	855
1770 B1770	CRL 5893 CRL 5960	229	57	01/15/30	M	W	0	11/12/87	LN	NE	4	12/08/87	N	N	N	Y	VP/PL/BL neck RT	CR	None
— B1774		087	71	06/04/16	M	W	2	11/17/87	PE	AD	3B								
1781	CRL 5894	141	66	04/24/21	F	W	3	11/27/87	PE	BA	3B	09/10/87	Y	Y	Y	N	VP/PL chest RT	PD	8315

1788	*	192	57	02/15/30	M	W	1	12/15/87	BM	SC	E	09/11/87	Y	N	Y	Y	VP/PL, CT/VP/PL-PR (IVBR)	PR	8313
1792	CRL 5895	260	50	10/27/37	M	W	1	12/10/87	PE	AD	4	01/08/88	N	N	N	Y	VP/PL; spine RT	PD	8315
1793	CRL 5896	063	52		F		0	12/11/87	LU	AD									
1819 B1819	CRL 5897	078	55	11/15/31	F	W	2	01/26/88	LN	AD	3	08/17/87	Y	N	Y	Y	VP/PL	PR	8315
1824 B1824		165			M			01/27/88	LN	LC									
— B1826		189	41	07/11/46	M	B	1	02/23/88	PE	AD	3B	02/24/88	N	N	N	Y	VP/PL Chest RT; no cell line	PD	8315
— B1830		103			M												No cell line		
1836	CRL 5898	228	52	10/06/35	M	W	1	02/12/88	LU	SC	L	07/15/86	Y	Y	Y	Y	VAC, VP, RT, PCI; VP/PL	CR	854
1838	CRL 5899	274			F			02/18/88	LU										
1869	CRL 5900	094	58	07/30/29	M	W	1	03/23/88	PE	SQ	4	01/28/88	Y	Y	Y	Y	VP/PL; brain RT	ID	8315
1870	CRL 5901	304			F			03/25/88	CE	SC									
1876	CRL 5902	253	59	09/17/28	M	W	1	04/01/88	LN	SC	E	04/11/88	N	N	N	Y	VP/PL, PCI	CR	8313
1881		253	59	09/17/28	M	W	1	04/07/88	BM	SC	E	04/11/88	N	N	N	Y	VP/PL, PCI, BM-R	CR	8313
1882	CRL 5903	253	59	09/17/28	M	W	1	04/07/88	BM	SC	E	04/11/88	N	N	N	Y	VP/PL, PCI, BM-L	CR	8313
— B1888		182	57	09/17/30	F	W	1	04/15/88	PE	AD	1	09/02/87	Y	N	Y	Y	TAMOX. no cell line	SD	
1904		079	44	02/23/44	M	W	0	04/21/88	LN	AD	4	04/28/88	N	N	N	Y	CAP, (IVBR); MMC, VEL, PL, VP16	PD	8315
— B1913		236	69	04/17/19	F	W	2	04/28/88	PE	BA	1	06/18/87	N	N	N	Y	Wedge resect.		8315
1915	CRL 5904	095	61	09/26/26	F	W	1	04/28/88	BR	NS	4	05/12/88	N	N	N	Y	Brain and chest RT	PR	None
1926	CRL 5905	115	27	07/14/60	M	W	1	05/11/88	LN	SC	E	05/13/88	N	N	N	Y	VP/PL	CR	8313
— B1928		245	69	01/10/19	F	W	1	05/15/88	LN	SQ	3A	07/07/88	N	N	N	Y	RT		
1930	CRL 5906	196	41	03/18/47	M	W	1	05/16/88	LN	SC	L	06/14/88	N	N	N	Y	VP/PL; RT mediast	CR	None
1934		272	44		M	H	1	06/06/88	CO	AD	2	06/06/88	N	N	N	N	Resect. sigmoid; LN 40/40 negative		
1944	CRL 5907	233	62	09/22/25	F	W	2	06/15/88	ST	AD	3B	03/03/88	Y	Y	N	N	RT chest SC node		None
1954		070			F			06/21/88	LU										
1963 B1963	*	049	56	02/18/32	M	B	1	06/29/88	LU	SC	L	07/13/88	N	N	N	Y	VP/PL chest RT PR; VAC-CR	CR	855
— B1964		133																	
1968		102			F			07/01/88	ST										
1971		039			M			07/01/88	CO										
1974		117			F			07/11/88	LN										
1975	CRL 5908	117			F			07/11/88	LU										
1977		250	71	08/15/16	M	W	1	07/13/88	PE	ME	4	08/09/88	N	N	N	Y	VP/PL, (IVBR), RT to soft tissue	PD	8315
1993 B1993	CRL 5909	099	47	07/04/41	F	W	1	08/16/88	LN	AD	3A								
1994	CRL 5910	153	69	08/11/19	F	W	0	08/17/88	LN	SC	E	11/12/87	Y	Y	Y	Y	VAC; VP/PL chest RT	CR	854
2007		221	53		M		1	08/26/88	LN	SQ	3A	11/19/87	Y	Y	N	Y	Chest RT, VP/PL	NC	8315

Part 1. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH NCIBL	ATCC #	ID	Age	DOB	Sex	R	PS	Cell line DT	SOS	DX	ST	1ST RX date	PRRX	PRT	PRCT	RXAF	Drugs	RS	PRO
2009 B2009	CRL 5911 CRL 5961	111	68	12/03/19	F	W	1	08/29/88	LN	AD	4	07/11/88	Y	N	Y	Y	DHLP chest RT	PD	8315
— B2015		106			F														
2023	CRL 5912	035	26	08/21/62	M	W	1	09/09/88	LN	AD	3A	09/20/88	N	N	N	Y	VP/PL, RT	PR	None
2028 B2028	CRL 5962	204	72	08/08/16	M	W	3	09/13/88	LN	SC	E	11/07/88	N	N	N	Y	VP/PL, 3 cycles	PR	8313
2029	CRL 5913	153	69	08/11/19	F	W	0	09/14/88	LN	SC	E	11/12/87	Y	Y	Y	Y	VAC, VP/PLAT chest RT	CR	854
2030	CRL 5914	054			M			09/14/88	LN	AD									
— B2050		025			M														
2052 B2052	CRL 5915 CRL 5963	214	65	03/17/23	M	W	2	09/30/88	PE	ME	4	10/19/88	N	N	N	Y	CT/ADRIA/PL (IVBR)	PD	8315
— B2055		205			M														
2058		250	72	08/15/16	M	W	1	10/11/88	PE	ME	4	08/09/88	Y	N	Y	Y	VP/PL (IVBR), RT to soft tissue	PD	8315
2059	CRL 5916	037	55	08/19/30	M	W	1	10/12/88	LN	SC	E	01/14/86	Y	N	Y	Y	VP/PL; VAC-CR, CTX-PD	CR	8313
2066	CRL 5917	187	70	08/08/18	F	W	0	10/25/88	LU	MI	1	10/25/88	N	N	N	N	LUL resect.		
2073	CRL 5918	099	47	07/04/41	F	W	1	11/01/88	LU	AD	3A		Y	N	N	Y	PRE-OP VP/PL; resect	CR	
2077 B2077	CRL 5919 CRL 5964	195	58	07/04/30	M	W	1	11/15/88	LN	AD	4	11/29/88	N	N	N	Y	VP/PL	PD	8315
2081	CRL 5920	032	59	02/20/29	F	W	2	11/22/88	PE	SC	E	07/02/88	Y	Y	Y	N	VP/PL; VAC; chest RT	PR	8313
2085	CRL 5921	173	45		M			11/23/88	LU	AD									
2086		173	45		M			11/23/88	LN	AD									
2087 B2087	CRL 5922 CRL 5965	179	69	12/11/18	M	W	1	11/25/88	LN	AD	1	10/13/81	N	N	N	Y	Resect 10/88 recur; VP/PL	PD	8315
2106	CRL 5923	229	58	01/15/30	M	W	0	12/15/88	LN	NE	4	12/08/87	Y	Y	Y	N	VP/PL/BL neck RT	CR	None
2107 B2107	* CRL 5966	121	36	04/13/52	M	B	1	12/15/88	BM R	SC	E	12/19/88	N	N	N	Y	VP/PL; VP/PL/CT (IVBR)	PR	8313
2108	*	121	36	04/13/52	M	B	1	12/15/88	BM L	SC	E	12/19/88	N	N	N	Y	VP/PL; VP/PL/CT (IVBR)	PR	8313
2110	CRL 5924	201						12/22/88	PE										
2115		064	68	01/21/20	M	W	2	12/30/88	PE	AD	3B	04/02/89	N	N	N	Y	VP/PL	SD	
2122 B2122	* CRL 5967	225	46	09/25/42	F	W	4	01/25/89	PE	AD	4	01/27/89	N	N	N	Y	VP/PL spine RT	PD	8315
2126 B2126	CRL 5925 CRL 5968	188	65	07/27/23	M	W	1	02/03/89	PE	LC	3B		N	N	N	U			
2127		015																	
2135	CRL 5926	022						02/24/89	LU										
2141 B2141	CRL 5927 CRL 5955	037	58	08/19/30	M	W	1	03/02/89	LN	SC	E	01/14/86	Y	N	Y	Y	VP/PL; VAC; CTX MOAB, 2A11-PD	CR	8313
2145		230			F			03/10/89	LU										
2170	CRL 5928	234			M			04/25/89	LU	SQ									

2171	CRL 5929	120	50	09/05/38	M	W	2	04/25/89	PE	SC	E	09/12/88	Y	Y	Y	Y	VP/PL; VAC; brain RT	PR	8313
B2171	CRL 5969																		
2172	CRL 5930	198			F			05/04/89	LU										
2195	CRL 5931	137	67	12/28/21	M	W	3	06/05/89	BM	SC	E	06/14/89	N	N	N	Y	VP/PL brain RT bone RT	ID	8313
B2195	CRL 5956								R										
2196	CRL 5932	137	67	12/28/21	M	W	3	06/05/89	BM	SC	E	06/14/89	N	N	N	Y	VP/PL brain RT bone RT	ID	8313
									L										
2198	CRL 5933	137	67	12/28/21	M	W	3	06/07/89	LN	SC	E	06/07/89	N	N	N	Y	VP/PL brain RT bone RT	ID	8313
—		071			M			07/25/89	LU										
B2222																			
2227	CRL 5934	082	54	05/18/35	M	W	1	08/24/89	LU	SC	E	09/13/89	N	N	N	Y	VP/PL, VC/AD/VP (IVBR), Brain RT	PR	8313
2228	CRL 5935	167			F			08/31/89	LU	AD									
2250	CRL 5936	243	46	07/02/43	M	W	1	10/03/89	LN	AD	3B	11/02/89	N	N	N	Y	CMC (IVBR)	PD	8315
2258		243	46	07/02/43	M	W	1	11/01/89	PE	AD	3B	11/02/89	Y	N	Y	Y	CMC (IVBR)	PD	8315
2284		161	63	01/18/26	F	W	1	01/04/90	LU	SQ	3A		N	N	N	Y	RT		
2286	CRL 5938	060	57	02/12/32	F	W	1	01/05/90	LU	MI	1	01/05/90	N	N	N	N	None		
2291	CRL 5939	088			M			01/11/90	LN	AD									
2330	CRL 5940	034	57	12/05/32	F	W	1	04/19/90	LN	SC	L	05/02/90	N	N	N	Y	VP/PL, VAC RT	CR	855
2332		309			M			04/20/90	BM	SC									
2342	CRL 5941	157	55	03/01/35	M	W		04/27/90	LU	AD	3A								
2347	CRL 5942	252	54	05/23/35	F	W	1	05/09/90	LU	AD	1	05/09/90	N	N	N	N	RUL Resect.		
B2347	CRL 5970																		
2365		006							CO										
2369		026			M			06/26/90											
2373	CRL 5943	163			M			07/03/90											
2380	*	001			F														
2405	CRL 5944	036	47	03/11/43	M	W		09/07/90	AS	AD	4		N	N	N	N	None		
2409		164	57	08/17/33	M	W	0	09/13/90	BO	AD	3A	04/17/90	N	N	N	Y	VP/PL	NC	8315
2444	CRL 5945	154			M			11/20/90											
2452	CRL 5946	166			M			11/27/90											
2461		007								ME									
2509		016																	
2527		155	73	06/25/17	M	W	0	05/15/91	LU	SC	L	07/08/91	N	N	N	Y	VP/PL ADJ	ND	None
2540		142	49	10/25/41	F	W	2	06/21/91	LN	AD	3B	06/26/91	N	N	N	Y	VP/PL, RT	PR	
2552		310			M			08/06/91	BM	SC									
2580		017																	
2591		008								ME									
2594		018																	
2595		009								ME									
2596		010								ME									
2597		019																	
2600		011								ME									
2618		012								ME									
2679		311			F			07/09/92	BM	SC									
2691		013								ME									
2706		014								ME									

TABLE IV. (Part 2). NCI-Navy Medical Oncology Branch Cell Line Data Base: Clinical and Cell Culture Information

NCIH	DDC	LATERXDT	Other RX	Comments	RES	DEATHDT	DXDATE	SMK	PCKYRS	Medium	SCSUBTYPE/ CLINESUB
0023	NEG					07/24/77	08/31/76	Y	40	R5	
0028	1.9					02/09/77	09/22/76	Y	29	R10	
0060	182					07/02/77	10/26/76	Y	53	R10	21/C
0064	59					11/02/77	01/31/77	Y	30	R10	22/C
0069	590	08/15/77	CTX/ADR		PD	09/23/77	05/01/76	U		R10	21/C
0078		11/15/77	Topical mustard			06/22/78	07/30/76			R10	
0082	NEG					01/09/78	07/19/77	Y	U	R10	22/40/V
N0087				Gastric primary						R10	
0102						08/19/79	04/30/77			R10	
0123	517					08/25/80	02/15/80	U			22/C
0125	NEG			Adenosquamous		05/04/79	10/26/78	Y	50	R5	
0128	508	06/15/78	VP/PL		PD	01/26/79	02/13/78	Y	60	R10	21/22/C
B0128	NEG									R10	
0146	553	03/19/79	RT			04/01/79	04/10/78	Y	100	R10	21/C
0157	NEG					08/10/79	04/30/79	Y	U	R5	
N0177	NEG	04/29/77	Chest RT, CMC		PD	07/02/77	12/26/76	Y	53		21/V
0182	219	09/05/79	DCM		PD	11/01/79	05/15/78	U		R10	22/C
0187	22					10/21/80	09/25/79	Y	50	R5	22/C
0196	NEG	11/01/79	CMC/PL		PD	01/17/80	12/01/77	U		R10	22/V
0209	333			Died before treatment		12/23/79	12/15/79	U		IMDM10	22/C
B0209	NEG									R10	
0211	NEG	01/17/80	MTX		PD	02/10/80	11/27/78	Y	35	R10	22/V
0220	277					05/18/80	02/15/80	U		R10	22/C
0226	NEG			No data						R10	
0249	573									R10	22/40/C
0250	493					12/10/80	06/17/80	U		R10	/C
0285	500	03/27/81	VP16		PD	04/11/81	11/11/80	Y	17	R10	22/C
0289	NEG					12/31/80	11/15/80	Y	30		22/V
B0289	NEG										
0290	NEG			No data							
0292	NEG					01/02/81	09/15/80	N	0	R10	
0295				No data						RSP	
0298	40	11/07/80	AZQ		PD	12/12/80	05/15/79	U			22/C
0322	NEG			No RX for NSCCL; 2nd primary		03/31/81	02/15/81	Y	60	R5	
0324	NEG					08/09/81	03/02/81	Y	80		
0345	788	06/18/81	RT bone			12/14/81	10/16/79	Y	60	HI-2	22/C
0358	NEG			No data						R5	
0360	ND			Extra-osseus Ewing's sarcoma							/V
0369	12	09/30/81	VP; chest RT		PD	11/10/81	05/01/81	Y	66		22/C
0372	NEG					11/12/81	06/15/81	U			/V

0378	947	09/29/81	VP16/MMC		PD	12/12/81	04/07/81	Y	50	R5	22/C
0379	ND	09/29/81	VP, MMC; neck shoulder RT		PD	12/12/81	04/07/81	Y	50		22/C
N0390	175	10/29/79	CMC		PD	01/23/81	02/02/79	U			/C
N0408	183	01/15/80	PLAT		PD	02/15/80	03/27/79	U			/C
N0417	NEG									R5	/V
0432	9			No data							/C
0433	NEG			No data							/V
0441	NEG			D/C for RX at other facility			05/25/82	U		R10	
0446	NEG					06/11/82	10/15/81	Y	80	R10	22/V
0449	98	06/10/82	VP/PL		PD	08/09/82	09/24/81	Y	150		22/C
0450	657	06/10/82	VP/PL		PD	08/09/82	09/24/81	Y	150		22/C
0460	NEG			No data						R10	
0462	52					09/17/82	08/04/82	U			/C
0463	114					09/17/82	08/04/82	U			/C
0478	71			No data							22/C
0498	97			No data						R10	
0508	163			GI primary; no data						R10	
0510	505	12/28/83	VP/PL	Small cell, no primary at DX	PD	04/22/84	08/01/80	Y	70	F12K10	
0513	NEG			HX of asbestos exposure		04/23/84	07/15/81	U		R10	
0520	NEG			No data						R10	
0522	NEG	08/22/84	CAP(IVBR)	11/18/82 R pneumonectomy	PD	10/21/84	11/18/82	Y	60	R5	
0524	NEG	11/30/82	VP/PL		PD	01/25/83	02/08/82	Y	30	R10	21
0526	NEG	12/01/82	RT			03/19/83	11/15/82	Y	30	R5	22
0548	27			RX unknown; GI primary			01/20/83	U		A4	
0568	77					03/02/83	02/18/83	Y	55		22/C
0571		08/18/82	VP/PL		PD	01/28/83		Y	60		22
0578	4	03/24/83	VP/PL		PR	08/06/83	07/30/81	Y	30		/C
0580	NEG	03/11/83	CCNU/MTX		PD	04/06/83	01/15/82	U			/C
N0592	204			No data						R10	/C
0596	NEG			No chemo; adenosquamous		04/23/84	06/23/82	U		R10	
0606	77	05/13/83	VP/PL		PD	06/29/83	06/01/82	Y	20		21/C
0615	ND			Died before therapy		08/25/83		U			
0618	37					02/04/84	07/15/83	Y	60		22/C
0620	2	06/01/83	PLAT		PD	08/30/83	09/01/82	Y	60		21/C
0630	189			GI primary, no data						R10	
0640	NEG			No further RX here			10/13/83	U			
0647	NEG					10/26/83	05/04/83	U		R10	
0650	NEG			NSCLC; No data						A4	
0660	550			Possible prostate primary		11/22/83	11/04/83	Y	28	HI-0	22
0661	4.4	04/25/84	CBDCA		SD	06/22/84	07/15/83	U		R10	
0676	NEG	04/12/84	CBDCA		SD	05/29/84	05/13/83	U		A4	
0678	18	04/05/84	CTX/CCNU/VC		PD	06/29/84	01/04/84	Y	100		21/C
0679	948	04/01/85	VP/PL; RT	ADENO/SCCL	PD	10/23/85	01/11/84	U			
0684	75			Colon primary; no data							

Part 2. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH	DDC	LATERXDT	Other RX	Comments	RES	DEATHDT	DXDATE	SMK	PCKYRS	Medium	SCSUBTYPE/ CLINESUB
0689	NEG					02/24/84	02/04/83	Y	80		21/C
N0691						04/24/81		Y	60		22
0711	244					05/11/84	01/17/84	Y	60	R10	22/C
0716	57			GI tumor; no data						R10	
0719	230	02/12/86	CBDCA/MTX		PR	10/20/86	03/12/84	Y	100	HI-5	22/C
0720	125			No data						HI-5	
0726	NEG	05/09/84	VP/PL (IVBR)	HX of ovarian CA	NC	10/31/84	09/29/83	N			
0727	499	07/17/84	Brain RT	No chemotherapy		08/19/84	04/24/84	Y	60	R5	
0735	ND	09/21/84	CBDCA		NC	12/18/84	10/15/83	Y	60		21/C
0738	ND					08/05/84	05/15/84	Y	30	HI-5	21
0740	191			Previous smoker, yrs unknown		05/05/86	05/15/84	Y	U	R10	22/C
0742	ND			GI primary; no data							
0747	ND			GI primary; no data						R10	
0748	149	07/25/84	CBDCA; VP16	8/84 chest RT	PD	11/19/84	08/24/83	Y	50	R10	22/C
0768	8			GI primary; no data							
0774	419	10/29/84	CT/MTX/VP IVBR	RT to brain and spine 1/85	PR	02/03/85	07/13/84	Y	30	HI-5	22/C
0792	ND	07/25/84	CBDCA; RT		PD	11/19/84	08/24/83	Y	50		22/C
0810	1155	09/05/85	CMC/VAP	Died presumed PD	CR	06/08/86	09/14/84	Y	32	HI-2	
0820	68			Death date unknown			05/06/84	U		A4	
0835	91			No data		10/15/88				A4	
0838	ND	02/20/85	VP/PL (IVBR)		PD	06/07/85	10/01/84	Y	80	R10	
0841	NEG					10/31/84	03/15/84	Y	70	HI-5	UNK/V
0847	3					11/29/84	08/08/84	Y	40	HI-5	22/C
0854	ND			No chemo or RT; probl. lung primary		01/15/85	04/15/84	U		R10	
0862	827	11/13/84	ADR/CTX/RT		NR	04/09/85	12/15/83	Y	110	—	22/C
0865	ND	11/14/84	VP16		PD	12/24/84	04/14/83	Y	40	R10	21/C
0889	273	12/26/84	VP/CTX/ADR	RT to brain METS 2/85	CR	05/14/85	07/06/84	Y	30	R10	21/C
0890	8					06/14/85	02/09/84	Y	46		22/C
0920	NEG	04/18/85	VP/PL; 7/85 RT brain METS	No IVBR	PD	09/01/85	12/11/84	Y	75	A4	
0929	ND			Myeloma; no data						R10	
0930	167	01/15/85	CBDCA; VP16 on 2/85; RT chest-PD		PD	05/28/85	05/01/84	U			/C
0958	ND			Colon primary; no data							
0962	NEG			SCLC; no data							
0969	ND			1972/77 RT for DIDL; axillary submandibular		12/16/85	02/13/85	N		A4	
1008	511					04/03/85	01/15/84	Y	40		22/C
1011	ND			Esthesioneuroblastoma							
1045	ND	05/15/85	CAP (IVBR); MTX, brain RT		NR	10/08/85	01/31/85	Y	70		21/C
1048	NEG			No data						HI-5	

1059	ND	10/24/86	MOAB 2A11	Specimen-pelvic mass	PD	03/17/87	05/21/85	Y	45	HI-10	/C
1061	ND					12/27/85	05/15/85	Y	34		21/C
1062	128					12/27/85	05/15/85	Y	34		21/C
1086	653					06/15/85	07/26/84	Y	100		22
1092	915		12/85 RT		PD	12/17/85	05/31/85	Y	120	HI-5	22/C
1105	210					12/18/85	06/15/85	Y	50	HI-5	22/C
1112				Myeloma; no data							
1155	297	11/13/85	VP/PL; brain RT 2/86		NC	05/01/86	06/27/85	Y	20	A4	
1173	529	07/24/86	CAP (IVBR)		NC	12/29/86	09/01/85	Y	70	R10	22/C
1184	954	01/10/86	RT brain			10/06/86	08/27/85	Y	75	A4	22
B1184	NEG									R10	
1185	397	10/01/85	VP/CT (IVBR); CBDCA 7/2/86	DHLP; RT < PD	PR	01/01/87	02/12/85	Y	30		21/C
1238	661					03/02/86	10/30/85	Y	130	R10	22
1264	ND	02/01/86	Brain RT	No chemo; adenosquamous		07/04/86	11/27/85	Y	70	R10	
1284	999					01/14/86	12/11/85	Y	60	A4	22/C
1299	NEG		RT L neck			03/25/86	10/04/85	Y	50	R5	
1304	126	04/15/86	IT MTX		PD	05/04/86	10/17/85	Y	70	HI-5	22/C
1315	ND	07/06/87	MOAB 2A11; RT chest, spine, brain		SD	10/09/89	02/03/86	Y	75		
1330	ND			Colon primary; no data							
1334	NEG	03/04/86	VP/PL	Source-epidural METS	ID	04/03/86	02/22/85	Y	60	R10	
1339	182	12/16/86	Brain RT			11/17/88	02/11/86	Y	60		22/C
B1339	NEG										
1341	22			Cervical tumor; no data						A4	
1355	NEG			No chemotherapy		04/02/86	01/23/86	Y	100	A4	
1373	NEG	09/10/85	VP/PL; FAM (IVBR)-PD	Source-pericardial fluid	NC	03/22/86	10/18/84	Y	30	R10	
1378	ND			No info after 5/23/86			03/24/86	U			
1385	443			No chemotherapy		07/31/87	04/11/86	Y	33	R10	
1387	ND			3/86 PD-D/C to private MD; Duke's C2 colon cancer			01/02/85				
1395	ND	09/01/89	RT to retroperitoneal METS			01/09/91	04/03/86	Y	15	R10	
B1395	ND									R10	
1404	3.8	11/08/86	Brain RT		PD	12/15/86	04/08/86	Y	20	A4	
1412	8.6			Colon cancer; no data							
1417	210					03/16/87	03/28/86	Y	50	R10	21/22/C
1435	ND			NSCLC; no data						A4	
1436	353	12/29/86	Brain RT			01/28/87	06/10/86	Y	75	HI-5	22/40/C
1437	ND			No RX for relapse		08/04/86	05/31/83	Y	70	R10	
B1437	ND									HI-5	
1440	ND			Colon cancer; no data							
1447	NEG			Last F-UP 6/25/87			07/09/86	U			
1450	NEG					07/24/86	07/03/86	Y	60	R10	22/C
B1450	NEG										
1451	ND					07/24/86	07/03/86	Y	60		22/C
1466	NEG					11/13/86	02/04/86	Y	30		

Part 2. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH	DDC	LATERXDT	Other RX	Comments	RES	DEATHDT	DXDATE	SMK	PCKYRS	Medium	SCSUBTYPE/ CLINESUB
—	ND					01/02/87	08/08/86	N			
B1474											
—	ND			Alive NED 4/28/92			09/11/86	Y	30		
B1489											
1498	NEG					09/29/87	09/23/86	Y	90		
1512	ND			NSCLC; no data							
1514	465	08/10/87	CT/PL/VP (IVBR)		CR	04/09/88	10/01/86	Y	30	HI-5	21/22/C
B1514	NEG		CTX/VCR-PD							R10	
			MTX-PD								
1522	129	10/24/86	CBDCA > PD		PD	12/25/86	05/15/86	Y	60	HI-5	21
			11/86 chest RT								
—	ND			Alive NED 9/18/90			10/31/86	U			
B1533											
1548	ND			NSCLC; no data							
1563	ND			NSCLC; no data						R10	
1568	NEG					07/17/87	12/22/86	Y	60	R10	
1570	647		12/23/86 lung resection	No follow-up information			10/07/86	U			
1573	ND	01/23/87	VP/PL		NC	03/13/88	12/10/86	Y	15	A4	
1581	NEG	2/87	RT bone METS	No chemotherapy	PD	04/19/87	01/29/87	Y	75	A4	
—	ND	04/20/87	DAUN/ARA-C, allopurinol	A.L.L. refractory to RX; D/C to home	NR		02/04/87	U			
B1582											
1592						05/16/87	01/28/87	Y	480		
—	ND					08/18/87	03/09/87	N			
B1601											
1607	NEG			Died of prob. CVA		04/03/88	03/04/87	Y	20	R10	22
B1607	NEG										
1608	ND			NSCLC; no data							
—	ND	08/15/87	RT brain METS	HX. of RUL ADENO 1969	PD	11/30/87	03/27/87	Y	45		
B1612											
1618	358	11/06/87	RT mediastin.			01/02/88	04/09/87	Y	50	HI-5	21/22
1622	231	11/06/87	RT mediastin.			01/02/88	04/09/87	Y	50	HI-5	21/22
1623	ND					11/01/87	02/26/87	Y	45	A4	
1628	233	11/87	Brain RT			01/27/88	04/16/87	Y	80		
—	ND			No data							
B1632											
1648	12	12/05/89	VP/PL		NC	05/17/90	05/15/87	Y	40	A4	
B1648	NEG									R10	
1650	ND					11/02/87	04/15/87	Y	10	R10	
1651	ND			NSCLC; no data		01/08/89				A4	
1652	ND			Colon cancer; no data							
1666	ND			3/87 bone METS		07/08/87	12/15/86	U		A4	
1670	ND			Colon cancer; no data							
1672	368			Alive 11/23/92			05/17/87	Y	138	HI-5	
B1672	ND									R10	

1688	1082	01/21/88	CCNU; IT MTX	Brain METS	PD	06/29/88	06/08/87	Y	70	R10	22
B1688	ND										
—	ND			No data							
B1690											
1693	NEG	03/29/88	VP/PL (IVBR) RT AXILLA		PD	03/25/89	07/01/87	Y	80	R10	
1694	61			Previously RX'D, dates UNK malignant ascites			09/08/86	U		HI-5	
—	ND			S/P ADENO stomach 1984; alive NED 9-24-90			07/15/87	U			
B1700											
1703	ND	07/02/90	RT bone METS			08/31/90	08/05/87	Y	50	R10	
1710	1	03/06/88	VP/PL; RT to chest, brain		PR	03/18/89	07/16/87	Y	60		
1717	ND			No data			08/25/87			A4	
1725	ND					11/19/87	09/04/87	U			
1734	54			NSCLC; no data		10/30/88				R10	
—	ND			No data							
B1740											
1755	ND	04/05/88	Chest, liver RT. no chemo			07/05/88	09/16/87	Y	60	R10	
1769	504	11/09/88	VP/PL; brain RT		PD	04/13/89	10/21/87	U			
1770	ND			12/88 PD No RX; alive stable			11/12/87	U		A4	
B1770	ND			09/25/90; UNK primary						A4	
—	ND		None	D/C home alive 4/15/88			10/17/87	U			
B1774											
1781	ND					01/19/88	08/28/87	Y	60	R10	
1788	119			3/88 probable PD, no RX		07/21/88	07/31/87	Y	60		22
1792	NEG					02/04/88	10/08/87	Y	30	R10	
1793	ND			No data; NSCLC		01/21/89				HI-5	
1819	ND	02/16/88	RT chest; VP/PL (IVBR) RT		PD	03/25/89	07/01/87	Y	80	A-4	
B1819	ND										
1824	ND			No data							
B1824	ND										
—	ND					12/19/88	01/14/88	Y	10		
B1826											
—	ND			No data							
B1830											
1836	268	02/17/88	MOAB2A11; RT brain, IT MTX		PD	04/05/88	07/01/86	Y	38	HI-5	
1838	ND			NSCLC; no data						R10	
1869	ND	04/01/88	Chest RT			04/03/88	12/22/87	Y	50	A4	
1870	388			Cervical tumor extrapulmonary SCCL						HI-5	
1876	40	01/05/89	CCNU/CT/VCR (IVBR)		PR	07/08/89	03/01/88	Y	40	HI-5	22/C
1881	46	01/05/89	CCNU/CT/VCR (IVBR)	Right	PR	07/08/89	03/01/88	Y	40		22
1882	58	01/05/89	CCNU/CT/VCR (IVBR)	Left	PR	07/08/89	03/01/88	Y	40	HI-5	22
—	ND	05/03/88	CMF-PD, CAF-PR brain RT	Breast cancer; recur 8/26/87 SC, PE, pulmonary nodules	PR	11/24/88	07/15/84	U			
B1888											
1904	NEG					08/25/88	04/04/88	Y	20		

Part 2. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH	DDC	LATERXDT	Other RX	Comments	RES	DEATHDT	DXDATE	SMK	PCKYRS	Medium	SCSUBTYPE/ CLINESUB
—	ND	05/24/88	VP/PL; RT chest	Lung, axillary node recur- rence	NC	04/05/89	06/18/87	N			
B1913											
1915	ND			Poorly differ. carcinoma		08/18/88	04/28/88	U		R10	
1926	NEG			Alive NED 6/8/92			02/29/88	N	0	HI-10	NS
—	ND			Alive W/CA 9/20/90; low dose MTX for rheum. arthritis			04/04/88	U			
B1928											
1930	ND			Last seen 12/15/88			05/16/88	U		R10	
1934	ND			No follow-up info colon cancer			06/06/88				
1944	39			4/88 relapse bone, subcutan. frac. femur, D/C local MD			02/12/88	Y	40	R10	
1954	ND			NSCLC; no data							
1963	273			Alive 2/25/93			06/29/88	Y	70		
B1963	ND										
—	ND			No data							
B1964											
1968	ND			NSCLC; no data							
1971	ND			Colon cancer; no data							
1974	ND			NSCLC; no data							
1975	ND			NSCLC; no data						R10	
1977	ND	11/15/88	RT soft tissue			06/08/89	05/31/88	N	0		
1993	ND			Alive 10/14/90			08/16/88	Y	30	R10	
B1993	ND										
1994	598	08/15/88	MOAB 2A11		PD	05/26/89	08/15/87	Y	52	A4	
2007						12/08/88	11/19/87	Y	40		
2009	NEG	09/29/88	VP/PL	Died of septic shock	ID	10/14/88	06/20/88	Y	30	HI-5	
B2009	ND									R10	
—	ND			No data							
B2015											
2023	3			D/C 12/20/88; no further f-up			08/12/88	U		HI-5	
2028	764			No 12 week response assess.		02/09/89	08/10/88	Y	20	R10	22
B2028	ND										
2029	793	08/15/88	MOAB 2A11		PD	05/26/89	08/15/87	Y	52	HI-5	
2030	NEG			NSCLC; no data		02/07/89				R10	
—	ND			No data							
B2050											
2052	ND					11/26/88	09/30/88	Y	40	R10	
B2052	ND									R10	
—	ND			No data							
B2055											
2058	ND	11/15/88	RT soft tissue			06/08/89	05/31/88	N	0		
2059	68	02/27/89	MOAB 2A11 chest RT VP/PL; MTX		PD	11/12/89	12/24/85	Y	50	HI-10	22

2066	127			SC/AD/SQ histology Alive NED 7/11/90			10/25/88	U		HI-5	
2073	ND			Lung resection 11/1/88; alive NED 10/14/90			08/16/88	Y	30	A4	
2077	ND					03/15/89	08/19/87	Y	68	HI-5	
B2077	ND									R10	
2081	NEG					11/27/88	05/23/88	Y	25	HI-10	22
2085	ND			NSCLC; no data		02/07/89				A4	
2086	NEG			NSCLC; no data		02/07/89		U			
2087	NEG	04/19/89	RT neck mass			06/23/89	10/13/81	Y	60	A4	
B2087	ND									R10	
2106	ND			12/88 relapse no RX 9/25/90 last follow-up			11/12/87	U		HI-5	
2107	321	07/20/89	Chest RT			09/15/89	12/03/88	Y	26	R10	22
B2107	ND										
2108	108	07/20/89	Chest RT			09/15/89	12/03/88	Y	26		22
2110	ND			NSCLC; no data						R10	
—	ND					06/21/89	12/30/88	U			
B2115											
2122	ND					04/03/89	01/25/89	Y	30	A4	
B2122	ND										
2126	ND					02/07/89	01/03/89	U		HI-5	
B2126	ND									R10	
2127				NSCLC; no data							
2135	ND			Lung cancer; no data						HI-5	
2141	12	03/28/89	Chest RT		PD	11/12/89	12/24/85	Y	50	HI-10	22
B2141	NEG		VP/PL; MTX							R10	
2145	ND			NSCLC; no data							
2170	ND			NSCLC; no data						R10	
2171	NEG	05/09/89	Chest RT	RX UNK.		05/18/89	07/28/88	Y	150	HI-5	22
B2171	ND									R10	
2172	ND			NSCLC; no data						R10	
2195	328			Death due to ruptured aortic aneurysm		07/13/89	06/01/89	Y	100	HI-5	22
B2195	NEG									R10	
2196	212			Death due to ruptured aortic aneurysm		07/13/89	06/01/89	Y	100	HI-10	22
2198	101			Death due to ruptured aortic aneurysm		07/13/89	06/01/89	Y	100	HI-5	22
—	ND			Lung cancer; no data							
B2222											
2227	338	05/11/90	Chest RT			04/07/91	08/24/89	Y	70	HI-5	22/40
2228	ND			NSCLC; no data						A4	
2250	ND					05/14/90	10/03/89	Y	30	A4	
2258	ND					05/14/90	10/03/89	Y	30		
2284	ND			Unknown f-up			09/25/89	U			
2286	ND			HX of 2 ST. 1 lung resections 1973, 1983. A NED 5-24-90			01/05/90	Y	60	A4	
2291	ND			NSCLC; no data						R10	

Part 2. NCI-Navy Medical Oncology Branch Cell Line Data Base (Continued)

NCIH	DDC	LATERXDT	Other RX	Comments	RES	DEATHDT	DXDATE	SMK	PCKYRS	Medium	SCSUBTYPE/ CLINESUB
2330	396	01/09/91	Brain RT			12/02/91	04/19/90	Y	65	HI-5	
2332	ND			No data							
2342	ND			NSCLC			04/26/90	U		HI-5	
2347	ND			Alive 9/10/90			05/09/90	U		R10	
B2347	ND									R10	
2365				Colon cancer; no data							
2369	ND			No data							
2373	ND			No data						R10	
2380	NEG			No data							
2405	ND		None	Gastric CA W/METS to liver ascites, BIL. pleural effusion		10/03/90	09/07/90	Y	75	A4	
2409				R lower lobectomy > 2/90 relapse adrenal, chest wall		10/25/90	05/01/89	Y	50		
2444	ND			No data						R10	
2452	ND			No data						R10	
2461				Mesothelioma; no data							
2509				NSCLC; no data							
2527				R lower lobectomy alive NED 11/4/91; HX of Dukes B-1 carcinoma, resected 1980			05/15/91	Y	40		
2540				Alive W/CA 10/28/91			06/03/91	Y	25		
2552				No data							
2580				NSCLC; no data							
2591				Mesothelioma; no data							
2594				NSCLC; no data							
2595				Mesothelioma; no data							
2596				Mesothelioma; no data							
2597				NSCLC; no data							
2600				Mesothelioma; no data							
2618				Mesothelioma; no data							
2579				No data							
2691				Mesothelioma; no data							
2706				Mesothelioma; no data							

LEGEND TO TABLE V

The following is the full description of the column headings.

A NCI cell line number
B full cell line name
C ATCC cell line number
D culture method of cell line growth under indicated culture conditions
E growth rate
F p53 mutation exon number as determined by SSCP
G location of mutated p53 codon
H p53 amino acid substitution
I nucleotide change for p53 mutations
J Loss of heterozygosity for p53 at 17p
K Loss of heterozygosity at MCC locus on 5q
L Loss of heterozygosity at APC locus on 5q
M Loss of heterozygosity at IL3 locus of 5q
N amino acylase enzyme level as marker for gene product coded by 3p
O Rb protein level by Western blot (range; 0, trace, 1, 2, 3)
P p53 protein level by Western blot using pAb-1801 (code: first letter; L—light, M—medium, S—strong band intensity; second letter; R— rearranged, N—normal, 0—none detected)
Q Southern blot result (code: nl—normal, 3′ or 5′ indicate where the abnormality is located)
R Rb Messenger RNA expression data from Northern blot (range; 0, trace, 1)
S Rb protein expression by Western blot (mutant, positive or negative expression)
T p16 protein expression (negative or positive)
U p53 Type of DNA abnormality
V p53 messenger RNA expression by Northern blot (range; 0, trace, 1 and then abnl indicates an abnormal message size)
W presence of K-ras mutation, codon location and nucleotide sequence if available
X nucleotide sequence of the first base of codon 12
Y pattern of K-ras codon 12 mutation as identified by designed RFLP method (*BST*/NI digestion) for wild type compare to mutant (Pattern I—equal intensities of mutant and wild type bands, Pattern IIa—mutant bands in great excess, Pattern IIb—complete absence of wild type bands)
Z Drug sensitivity testing for PALL
AA D3S4; polymorphic markers for the short arm of chromosome 3 (3p)
AB D3S30; polymorphic marker for the short arm of chromosome 3 (3p)
AC D3S3; polymorphic marker for chromosome 3 (3p)
AD DNF15S2, polymorphic marker for chromosome 3 (3p)
AE D3S32; polymorphic marker for chromosome 3 (3p)
AF D3S2; polymorphic marker for chromosome 3 (3p)
AG erb AB/H; polymorphic marker for chromosome 3 (3p)
AH erb AB/R; polymorphic marker for chromosome 3 (3p)
AI raf/R1; polymorphic marker for chromosome 3 (3p)
AJ raf1/Bgl polymorphic marker for chromosome 3 (3p)
AK raf/Taq polymorphic marker for chromosome 3 (3p)
AL D3S18; polymorphic marker for chromosome 3 (3p)
AM D3S17; polymorphic marker for chromosome 3 (3p)
AN YZ22/BAM; Polymorphic marker for 17p
AO c-myc amplification
AP c-myc expression
AQ n-myc amplification
AR n-myc expression
AS 1-myc amplification
AT 1-myc expression
AU 3p abnormalities
AV 3pN-number of normal 3p alleles
AW 3pA-number of abnormal 3p alleles
AX mode—modal chromosome number
AY Range—range of chromosome number per cell.

TABLE V. Range of In Vitro Data

A	A	B	C	D	E	F	G	H	I	J	K
1	NCI_No	Name	ATCC_No	CultureM	Growth	Exon	AA#	Subst	Mutation	LOH	MCC
2		SNU-1									
3		SNU-16									
4		SNU-5									
5		SNU-55									
6		UMC-11									
7	1	SNU-C1		mixed							
8	2	SNU-C2A	CCL 250.1	adherent							
9	3	SNU-C2B	CCL 250	adherent							
10	4	SNU-C4		adherent							
11	5	SNU-C5		adherent							
12	23	NCI-BL23		adherent	slow						
13	23	NCI-H23	CRL 5800	adherent	slow	7	246	M-I	ATG to ATC(miss	LOH	
14	28	NCI-H28	CRL 5820								
15	60	NCI-H60	CRL 5821	floating							
16	64	NCI-H64	*								
17	69	NCI-H69	HTB 119	floating	fast						
18	82	NCI-H82	HTB 175	floating	fast	4	125		ACG to ACT (spl acc;inc intron 4		
19	87	NCI-N87	CRL 5822								
20	123	NCI-H123		floating							
21	125	NCI-BL125		adherent							
22	125	NCI-H125	CRL 5801	adherent		7	239		AAC to AAaC+1bp	LOH	
23	128	NCI-BL128	CRL 5947	floating	fast						
24	128	NCI-H128	HTB 120	floating	fast						
25	146	NCI-H146	HTB 173	floating					nd		
26	157	NCI-BL157		adherent							
27	157	NCI-H157	CRL 5802	adherent		8	298		CAG to TAG (stop)	H	
28	177	NCI-N177		floating							
29	179	NCI-N179		floating		4			ACT to ACG		
30	182	NCI-H182	*	floating					nd		
31	187	NCI-H187	CRL 5804	floating	fast	7	241				
32	196	NCI-H196	CRL 5823	floating		5			nd		
33	207	NCI-H207									
34	209	NCI-BL209	CRL 5948	floating	fast						
35	209	NCI-H209	HTB 172	floating	fast						
36	211	NCI-H211	CRL 5824	floating	fast	7	248	R-Q	CGG to CAG miss		
37	220	NCI-H220	CRL 5825	floating							
38	226	NCI-BL226		adherent							

A	A	B	C	D	E	F	G	H	I	J	K
39	226	NCI-H226	CRL 5826	adherent		5	158	R-L	CGC to CTC	LOH	
40	230	NCI-N230		floating							
41	231	NCI-N231		floating							
42	249	NCI-H249	CRL 5827	floating		5			no		
43	250	NCI-BL250		floating							
44	250	NCI-H250	CRL 5828	floating							
45	285	NCI-H285	CRL 5829	floating							
46	289	NCI-H289		floating							
47	290	NCI-H290		adherent							
48	292	NCI-BL292									
49	292	NCI-H292	CRL 1848						neg		
50	295	NCI-H295	CRL 10296								
51	298	NCI-H298		floating							
52	322	NCI-H322	CRL 5806	adherent		7	248	R-L	CGG to CTG(miss	LOH	
53	324	NCI-H324		adherent	very slow	7	249	R-S	AGG to AGC	LOH	
54	345	NCI-H345	HTB 180	floating		8			nd		
55	358	NCI-BL358		adherent	fast						
56	358	NCI-H358	CRL 5807	adherent	fast				Homozygous deletion		
57	360	NCI-H360		floating							
58	369	NCI-H369		floating							
59	372	NCI-H372		floating							
60	378	NCI-H378	CRL 5808	floating		5			nd		
61	379	NCI-H379		floating							
62	390	NCI-BL390		floating							
63	390	NCI-N390		floating							
64	408	NCI-N408									
65	417	NCI-N417	CRL 5809								
66	432	NCI-H432		floating							
67	433	NCI-H433		floating							
68	434	NCI-H434		adherent	fast						
69	441	NCI-H441	HTB 174			5	158	R-L	CGC to CTC	LOH	
70	446	NCI-H446	HTB 171	floating	BN						
71	449	NCI-H449		floating							
72	450	NCI-H450		floating							
73	460	NCI-BL460		adherent							
74	460	NCI-H460	HTB 177	adherent					wt		
75	462	NCI-H462		floating							
76	463	NCI-H463		floating							

TABLE V. Range of In Vitro Data (Continued)

A	A	B	C	D	E	F	G	H	I	J	K
77	478	NCI-H478		floating							
78	498	NCI-H498	CCL 254	mixed							
79	508	NCI-H508	CCL 253	adherent							
80	510	NCI-H510	HTB 184	floating	intermedi	8	282	R-G	CGG to GGG(miss		
81	513	NCI-H513	CRL 5830	adherent	slow						
82	520	NCI-H520	HTB 182	adherent		5	146		TGG to TGA (stop)	LOH	
83	522	NCI-H522	CRL 5810	adherent		6	191		CCT to CT, 1bp	LOH	
84	524	NCI-H524	CRL 5831	floating		5			nd		
85	526	NCI-H526	CRL 5811	floating	fast	i3	33-125(int 3, AG to AC; spl acc; del ex 4				
86	537	NCI-H537									
87	548	NCI-H548	CCL 249	adherent							
88	568	NCI-H568		floating							
89	578	NCI-H578		floating							
90	580	NCI-H580		floating							
91	592	NCI-N592	CRL 5832	floating							
92	596	NCI-H596	HTB 178	adherent		7	245	G-C	GGC to TGC	LOH	
93	606	NCI-H606		floating							
94	615	NCI-H615		floating							
95	618	NCI-H618		floating							
96	620	NCI-H620		floating							
97	630	NCI-H630	CRL 5833	adherent							
98	640	NCI-H640	*	adherent							
99	647	NCI-H647	CRL 5834	adherent		i7	GT to TT; spl don; inclu 5' i7 to STOP				
100	650	NCI-H650	CRL 5835	floating	fast	5	164	K-N	AAG to AAT	LOH	
101	660	NCI-H660	CRL 5813	floating	fast						
102	661	NCI-H661	HTB 183	adherent	slow	6	215	S-I	AGT to ATT	H	
103	676	NCI-H676	HTB 179	floating		6	217	V-L	GTG to TTG	H	
104	678	NCI-H678		floating							
105	679	NCI-H679		floating		4	102		ACC to AC, 1bp	LOH	
106	684	NCI-H684		adherent							
107	689	NCI-H689		floating							
108	711	NCI-H711	CRL 5836	floating							
109	716	NCI-H716	CCL 251	floating							
110	719	NCI-H719	CRL 5837	floating					nd		
111	720	NCI-H720	CRL 5838	floating		5	176	C-W	TGC to TGG	LOH	
112	726	NCI-H726		floating					wt		
113	727	NCI-H727	CRL 5815	adherent	slow	5	165 -166, 9bp dupl			LOH	
114	735	NCI-H735	*	floating							

A	A	B	C	D	E	F	G	H	I	J	K
115	738	NCI-BL738		floating							
116	738	NCI-H738	CRL 5839	floating		8	267	R-P	CGG to CCG		
117	740	NCI-BL740		floating	fast						
118	740	NCI-H740	CRL 5840	floating	fast						
119	742	NCI-H742		adherent							
120	747	NCI-H747	CCL 252	adherent							
121	748	NCI-H748	CRL 5841	floating							
122	749	NCI-H749									
123	768	NCI-H768		adherent							
124	774	NCI-H774	CRL 5842	floating	fast	10	342		CGA to TGA (stop)		
125	792	NCI-H792		floating							
126	810	NCI-BL810		floating							
127	810	NCI-H810	CRL 5816	floating		8			nd	LOH	
128	820	NCI-BL820		floating							
129	820	NCI-H820	HTB 181	floating		8	284	T-P	ACA to CCA(miss	LOH	
130	835	NCI-H835	CRL 5843	floating		i4	in4, CGG to CAT(spl			LOH	
131	838	NCI-H838	CRL 5844	adherent					wt		
132	841	NCI-H841	CRL 5845	floating							
133	847	NCI-H847	CRL 5846	floating			98I				
134	854	NCI-H854	CRL 5847	floating		8	285	E-K	GAG to AAG	LOH	
135	862	NCI-H862	CRL 5848	floating							
136	865	NCI-H865	CRL 5849	floating							
137	889	NCI-H889	CRL 5817	floating	fast	7	242	C-S	TGC to TCC(miss		
138	890	NCI-H890		floating							
139	920	NCI-H920	CRL 5850	floating		i5	AG to AC (spl acc site			LOH	
140	929	NCI-H929	CRL 5851								
141	930	NCI-H930			fast						
142	958	NCI-H958		floating							
143	962	NCI-H962									
144	969	NCI-H969	CRL 5852	floating					no		
145	1008	NCI-H1008		floating							
146	1045	NCI-H1045	*	floating					nd		
147	1048	NCI-H1048	CRL 5853	floating	intermedi	8	273	R-C	CGT to TGT(miss		
148	1059	NCI-H1059	CRL 5854	floating							
149	1061	NCI-BL1061		floating							
150	1061	NCI-H1061		floating							
151	1062	NCI-H1062									
152	1086	NCI-H1086	*								

TABLE V. Range of In Vitro Data (Continued)

A	A	B	C	D	E	F	G	H	I	J	K
153	1092	NCI-H1092	CRL 5855	floating	fast	i6	int 6, AG to AC;spl acc;incl int 7 to STOP				
154	1101	NCI-H1101									
155	1105	NCI-H1105	CRL 5856	floating					nd		
156	1155	NCI-H1155	CRL 5818	floating	fast	8	273	R-H	CGT to CAT(miss	LOH	
157	1173	NCI-BL1173		floating							
158	1173	NCI-H1173	CRL 5857	floating							HET
159	1184	NCI-BL1184	CRL 5949	floating	fast						
160	1184	NCI-H1184	CRL 5858	floating	fast	10	334	G-V	GGG to GTG(miss		LOH
161	1185	NCI-BL1185		floating							
162	1185	NCI-H1185	*	floating							
163	1238	NCI-H1238	CRL 5859						nd		
164	1264	NCI-BL1264		adherent							
165	1264	NCI-H1264	CRL 5860	adherent		8	298	E-stop	CAG to TAG		
166	1284	NCI-H1284	CRL 5861			7	248	R-W	CGG-TGG		
167	1299	NCI-H1299	CRL 5803	adherent		5' intragenic deletion					
168	1304	NCI-H1304	CRL 5862	floating		7	234	Y-C	TAC-TGC		
169	1315	NCI-H1315									
170	1334	NCI-H1334	CRL 5863	adherent		6	224	E-D	GAG to GAC	LOH	
171	1339	NCI-BL1339	CRL 5950	floating							
172	1339	NCI-H1339	*	floating		i9	(int 9, GT to TT;spl don; incl int 9 to STOP				LOH
173	1341	NCI-H1341	CRL 5864	floating							
174	1355	NCI-H1355	CRL 5865	floating		8	285	E-K	GAG to AAG(miss	LOH	
175	1373	NCI-BL1373		adherent	slow						
176	1373	NCI-H1373	CRL 5866	adherent	slow	4	47	P-L	CCG to CTG(missense	LOH	
177	1378	NCI-H1378		adherent							
178	1385	NCI-H1385	CRL 5867	floating					wt		
179	1395	NCI-BL1395	CRL 5957	floating							
180	1395	NCI-H1395	CRL 5868	floating		4			nd	H	
181	1404	NCI-H1404	CRL 5819	floating		5	144		CAG to TAG (stop)	LOH	
182	1417	NCI-BL1417		floating							
183	1417	NCI-H1417	CRL 5869	floating		5	175		CGC-CC (frame shift)		LOH
184	1435	NCI-H1435	CRL 5870	floating		5	141	C-W	TGC to TGG	LOH	
185	1436	NCI-BL1436		floating	fast						
186	1436	NCI-H1436	CRL 5871	floating	fast	5	179	H-Q	CAT to CAG(miss		HET
187	1437	NCI-BL1437	CRL 5958	adherent							
188	1437	NCI-H1437	CRL 5872	adherent		8	267	R-P	CGG to CCG(miss	LOH	HET
189	1445	NCI-H1445									
190	1447	NCI-H1447		adherent							

A	A	B	C	D	E	F	G	H	I	J	K
191	1450	NCI-BL1450	CRL 5951	floating							
192	1450	NCI-H1450	*	floating		6	194	L-R	CTT to CGT(miss		LOH
193	1451	NCI-H1451		floating							
194	1466	NCI-H1466	*	adherent		4	89		CCC to CC, 1bp	LOH	
195	1474	NCI-H1474									
196	1479	NCI-H1479PF									
197	1498	NCI-H1498	*	adherent		i4	i4,CGG to CGT(spl			LOH	
198	1512	NCI-H1512		floating							
199	1514	NCI-BL1514	CRL 5952	floating	fast						
200	1514	NCI-H1514	CRL 5873	floating	fast	4	68		GAG to TAG (nonsense		LOH
201	1522	NCI-H1522	CRL 5874	floating							
202	1548	NCI-H1548		adherent							
203	1563	NCI-H1563	CRL 5875	adherent							
204	1568	NCI-H1568	CRL 5876						wt		
205	1570	NCI-H1570		floating					wt		
206	1573	NCI-H1573	CRL 5877	adherent		7	248	R-L	CGG to CTG	LOH	
207	1581	NCI-H1581	CRL 5878	mixed		5	144		CAG to TAG (stop)	LOH	
208	1583	NCI-H1583									
209	1607	NCI-BL1607	CRL 5953								
210	1607	NCI-H1607				5	151	P-H	CCC to CAC(miss		LOH
211	1608	NCI-H1608		adherent							
212	1618	NCI-H1618	CRL 5879	floating		7	248	R-L	CGG to CTG(miss		
213	1622	NCI-H1622	CRL 5880				missihg both 5' and 3' ends				
214	1623	NCI-H1623	CRL 5881	adherent		8	273	R-L	CGT to CTT	LOH	
215	1628	NCI-H1628	*			5	175	R-H	CGC-CAC		
216	1648	NCI-BL1648	CRL 5954	adherent							
217	1648	NCI-H1648	CRL 5882	adherent		4	35		TTG to TTtG 1bp	LOH	LOH
218	1650	NCI-H1650	CRL 5883	adherent		6	213		polymorphism-213		
219	1651	NCI-H1651	CRL 5884			5	176	C-Y	TGC to TAC	LOH	
220	1653	NCI-H1653							wt		
221	1666	NCI-H1666	CRL 5885			6	213		polymorphism-213		
222	1672	NCI-BL1672	CRL 5959	floating							
223	1672	NCI-H1672	CRL 5886	floating		8	266	G-V	GGA to GTA		
224	1688	NCI-BL11		adherent							
225	1688	NCI-H1688	CCL 257	adherent					nd		
226	1693	NCI-H1693	CRL 5887						wt		
227	1694	NCI-H1694	CRL 5888	floating							
228	1703	NCI-H1703	CRL 5889			8	285	E-K	GAG to AAG	LOH	

TABLE V. Range of In Vitro Data (Continued)

A	A	B	C	D	E	F	G	H	I	J	K
229	1710	NCI-H1710	*			8			GG to GT, splice donor site		
230	1717	NCI-H1717	CRL 5890								
231	1725	NCI-H1725		adherent					wt		
232	1734	NCI-H1734	CRL 5891	adherent		8	273	R-L	CGT to CTT	LOH	
233	1755	NCI-H1755	CRL 5892			7	242	C-F	TGC to TTC	LOH	
234	1769	NCI-H1769		floating							
235	1770	NCI-BL1770	CRL 5960								
236	1770	NCI-H1770	CRL 5893			7			yes		
237	1781	NCI-H1781	CRL 5894	floating		5	157	V-F	GTC to TTC	LOH	
238	1788	NCI-H1788	*	floating							
239	1792	NCI-H1792	CRL 5895	adherent		i6			GT to AT(spl don	LOH	
240	1793	NCI-H1793	CRL 5896	floating		6	209		AGA to TGA (stop)	LOH	
241	1819	NCI-BL1819		floating							
242	1819	NCI-H1819	CRL 5897	floating							
243	1824	NCI-H1824		adherent							
244	1836	NCI-H1836	CRL 5898								
245	1838	NCI-H1838	CRL 5899								
246	1869	NCI-H1869	CRL 5900	adherent		7	237	M-I	ATG to ATA		
247	1870	NCI-H1870	CRL 5901								
248	1876	NCI-H1876	CRL 5902	floating							
249	1878	NCI-H1878									
250	1881	NCI-H1881		floating		8	273	R-L	CGT to CTT		
251	1882	NCI-H1882	CRL 5903	floating		8	273	R-L	CGT to CTT		
252	1904	NCI-H1904		adherent		6	209		AGA to TGA (stop)	LOH	
253	1915	NCI-H1915	CRL 5904			8	291		AAG to TAG (stop)	LOH	
254	1926	NCI-H1926	CRL 5905	floating		6	213		CGA to TGA(nonsense)		
255	1929	NCI-H1929									
256	1930	NCI-H1930	CRL 5906								
257	1944	NCI-H1944	CRL 5907						wt		
258	1954	NCI-H1954		adherent							
259	1963	NCI-BL1963		floating							
260	1963	NCI-H1963	*	floating		5	147	V-D/H-R	GTT to GAT and 214 CAT to CGT		
261	1968	NCI-H1968		adherent							
262	1969	NCI-H1969		floating							
263	1974	NCI-H1974									
264	1975	NCI-H1975	CRL 5908								
265	1977	NCI-H1977									
266	1993	NCI-BL1993	*								

A	A	B	C	D	E	F	G	H	I	J	K
267	1993	NCI-H1993	CRL 5909								HET
268	1994	NCI-H1994	CRL 5910	floating							
269	2009	NCI-BL2009	CRL 5961								
270	2009	NCI-H2009	CRL 5911			8	273	R-L	CGT to CTT	LOH	NI
271	2023	NCI-H2023	CRL 5912						wt		
272	2028	NCI-BL2028	CRL 5962	floating							
273	2028	NCI-H2028		floating							
274	2029	NCI-H2029	CRL 5913	floating							
275	2030	NCI-H2030	CRL 5914						wt		
276	2052	NCI-BL2052	CRL 5964								
277	2052	NCI-H2052	CRL 5915								HET
278	2058	NCI-H2058									
279	2059	NCI-H2059	CRL 5916	floating							
280	2066	NCI-H2066	CRL 5917			5	157	V-F	GTC to TTC	LOH	
281	2073	NCI-H2073	CRL 5918			7	242	C-W	TGC to TGG	LOH	
282	2077	NCI-BL2077	CRL 5964								
283	2077	NCI-H2077	CRL 5919						wt		
284	2081	NCI-H2081	CRL 5920	floating					nd		
285	2085	NCI-H2085	CRL 5921	adherent							
286	2086	NCI-H2086				6	220	Y-S	TAT-TCT (missense)	LOH	
287	2087	NCI-BL2087	CRL 5965								
288	2087	NCI-H2087	CRL 5922			5	157	V-F	GTC to TTC(miss	LOH	LOH
289	2098	NCI-BL2098									
290	2098	NCI-H2098									
291	2106	NCI-H2106	CRL 5923			7	248	R-W	CGG to TGG(miss		
292	2107	NCI-BL2107	CRL 5966								
293	2107	NCI-H2107	*						nd		
294	2108	NCI-H2108	*								
295	2110	NCI-H2110	CRL 5924								
296	2122	NCI-BL2122	CRL 5967						no		
297	2122	NCI-H2122	*			5			nd	H	NI
298	2126	NCI-BL2126	CRL 5968								
299	2126	NCI-H2126	CRL 5925						wt		
300	2135	NCI-H2135	CRL 5926								
301	2141	NCI-BL2141	CRL 5955	floating	fast						
302	2141	NCI-H2141	CRL 5927	floating	fast	6	209		AGA-TGA (stop)		NI
303	2145	NCI-H2145		SF							
304	2170	NCI-H2170	CRL 5928								

TABLE V. Range of In Vitro Data (Continued)

A	A	B	C	D	E	F	G	H	I	J	K
305	2171	NCI-BL2171	CRL 5969								
306	2171	NCI-H2171	CRL 5929								
307	2172	NCI-H2172	CRL 5930	adherent							
308	2195	NCI-BL2195	CRL 5956								
309	2195	NCI-H2195	CRL 5931						nd		
310	2196	NCI-H2196	CRL 5932								
311	2198	NCI-H2198	CRL 5933								
312	2227	NCI-H2227	CRL 5934			i7	(int 7, AG to CG;spl acc; ins TCG ,stop 24 bp del ex 8)				
313	2228	NCI-H2228	CRL 5935	adherent							
314	2250	NCI-H2250	CRL 5936	floating		5	161	A-T	GCC to ACC	LOH	
315	2258	NCI-H2258		floating							
316	2280	NCI-H2280									
317	2284	NCI-H2284		floating							
318	2286	NCI-H2286	CRL 5938								
319	2291	NCI-H2291	CRL 5939	floating							
320	2330	NCI-H2330	CRL 5940								
321	2342	NCI-H2342	CRL 5941	adherent							
322	2347	NCI-BL2347	CRL 5970	adherent							
323	2347	NCI-H2347	CRL 5942	adherent					wt		
324	2373	NCI-H2373	CRL 5943								
325	2380	NCI-H2380									
326	2403	NCI-H2403									
327	2405	NCI-H2405	CRL 5944								
328	2444	NCI-H2444	CRL 5945								
329	2452	NCI-H2452	CRL 5946								

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
1	APC	IL3	AAcyl	Rb	p53	Rb DNA	Rb RNA	Rb protei	p16INk4 e	p53 DNA	p53 RNA	ras	K12	Ras mut p
2												+	+	
3													GGT	
4													GGT	
5												+	+	
6														
7													GGT	
8												+	+	
9														
10														
11														
12														
13		A		3	MN	nl	tr	pos	neg	246	1	K12	TGT	
14			88.7	2	tr									
15			2.4							nl	trace		GGT	
16													GGT	
17			0.8	0,0,0,tr		nl	pt spl mut	mut	pos	nl	trace		GGT	
18			13.7	0		nl	tr	neg	pos	splice mut	tr abnl		GGT	
19													GGT	
20								neg	pos					
21														
22			3.8	1,2	LR	nl	1	pos	neg	sm mut	1		GGT	
23														
24			0.25					neg	pos				GGT	
25			0.7					mut	pos				GGT	
26				0,1										
27		AB	51.7		LN							K12	CGT	I
28														
29														
30			3.5										GGT	
31		A	0	0,0,0		5'	0	neg	pos	nl	1		GGT	
32														
33								neg	pos					
34							nl RP							
35			23.7	3		nl	1,seq, pt	mut	pos	nl	trace		GGT	
36			22.7					pos	neg	248			GGT	
37														
38				0,tr										

TABLE V. Range of In Vitro Data (Continued)

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
39		A	14.5		LN	nl	1	pos	neg	nl	1		GGT	
40														
41														
42								mut	pos					
43														
44														
45														
46								neg	pos					
47			37.7											
48														
49				1	LN								GGT	
50				0										
51														
52				3,3	SN	nl	1						GGT	
53				4									GGT	
54			0		MR	3'	0	neg	pos	nl	1			
55														
56			28.7	3	-	nl	1	pos	neg	deleted	0	K12	TGT	I
57								pos	pos					
58														
59								neg	pos					
60			8.7			3'	0			nl	1		GGT	
61														
62														
63														
64														
65														
66														
67								neg	pos					
68														
69		A	25.7	4	MN			pos	neg			K12	GTT	
70			8.1	4				mut	pos					
71														
72														
73														
74			10.7	2	LN	nl	1			nl	1	K61CAT	GGT	IIb
75														
76														

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
77														
78													GGT	
79													GGT	
80			118.7	1	+	nl	tr	neg	pos	282	1		GGT	
81			30.5	3	tr									
82			4.7	4	LR					nl	reduced		GGT	
83		A	9.7	tr	LN	nl	1, nl RP	pos	pos				GGT	
84		A					0	neg	pos					
85				0		nl	0	neg	pos	splice mut	abnl size		GGT	
86														
87			83.7										GGT	
88														
89														
90														
91				tr		nl	tr						GGT	
92			36.7	0	MN	nl	0			nl	1		GGT	
93														
94														
95														
96								neg	pos					
97													GGT	
98			0.7											
99		A	9.3	2	LR					splice mut	abnl size	K13 GAC	GGT	IIb
100				2	LN							K61 CTA	GGT	IIb
101				2,tr						deletion	tr		GGT	
102		B	9.3	2,1	MN	nl	1	pos	neg	sm mut	1		GGT	
103				tr	LN						abnl size		GGT	
104								neg	pos				GGT	
105			3.8	0	0	3'	0						GGT	
106												+	+	
107								neg	pos					
108			0				tr						GGT	
109													GGT	
110								pos	neg				GGT	
111			4	tr	MN	nl	0						GGT	
112				1	0								GGT	
113			163.7	3,1	MN	nl	1			sm mut	1	K12	GTT	IIa
114						nl	0	neg	pos				GGT	

TABLE V. Range of In Vitro Data (Continued)

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
115														
116				0				neg	pos	267				
117														
118			0					neg	pos					
119														
120														
121							0						GGT	
122														
123													GGT	
124			3.7	0		nl	0	neg	pos	342			GGT	
125			0					pos	neg				GGT	
126														
127				4	0	nl	1						GGT	
128														
129				2	LN	nl	1			sm mut	1		GGT	
130			0.7	2	0	nl	0						GGT	
131		A		3	0	nl	1						GGT	
132			4.9			nl	1	pos	neg				GGT	
133			0			nl	tr						GGT	
134								pos	neg					
135			3.7					neg	pos					
136								pos	neg					
137			6.8			3'	0	neg	pos	242	reduced		GGT	
138														
139				tr	0					sm mut	reduced		GGT	
140														
141			1.2					neg	pos				GGT	
142														
143			2.9											
144				0	0					rearr	0		GGT	
145			0											
146				0										
147		AB		2						273			GGT	
148								neg	pos					
149														
150													GGT	
151								neg	pos					
152			0.2											

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
153		A	0			nl	1	neg	pos	splice mut	reduced		GGT	
154														
155						nl	1						GGT	
156			6.2	1	SN	nl	0	mut	pos			K61 CAT	GGT	
157														
158	LOH							neg	pos				GGT	
159														
160	NI					nl	1			334			GGT	
161														
162														
163														
164														
165			81.7	tr	tr			pos	neg			K12	CGT	
166						nl	0	neg	pos				GGT	
167					0							N61 AAA	GGT	
168						nl	0	neg	pos				GGT	
169														
170				2	SN								GGT	
171														
172	NI	B								splice mut				
173		A		2,4	-								GGT	
174				2	LN	nl	tr					K13 TGC	GGT	
175				2										
176					0	nl	1	pos	neg			K12	TGT	
177														
178				4	0	nl	1			nl	1	K12	TGT	I
179														
180													GGT	
181				1	0	nl	1						GGT	
182														
183	NI												GGT	
184						nl	1						GGT	
185														
186	NI	A				nl	spl mut d	mut	pos	179	1		GGT	
187														
188	NI			2	LR	nl	1						GGT	
189						nl								
190														

TABLE V. Range of In Vitro Data (Continued)

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
191														
192	LOH	A					0			194	1		GGT	
193														
194				4	0								GGT	
195														
196														
197					0								GGT	
198														
199														
200	NI							neg	pos	68				
201								neg	pos					
202														
203				4	LN			pos	neg				GGT	
204				4	LN								GGT	
205				4	LN							K12	TGT	I
206				2	SN								GGT	
207				2	0								GGT	
208														
209														
210	NI							neg	pos	151				
211														
212				tr										
213						nl	tr						GGT	
214				1	LN								GGT	
215		B		0				neg	pos					
216														
217	NI												GGT	
218				1	0			pos	neg				GGT	
219				2	MN								GGT	
220														
221				2	MN								GGT	
222														
223								neg	pos					
224														
225														
226				2	0								GGT	
227														
228				2	LR								GGT	

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
229				0	LR							K13 TGC	GGT	
230				3										
231					LR			pos	neg			K12	GTT	
232				0	SN							K13 TGC	GGT	
233				3	LN			pos	neg				GGT	
234														
235														
236														
237								neg	pos				GGT	
238										176				
239				2	0							K12	TGT	IIa
240					MN								GGT	
241														
242				2	-									
243														
244				0,tr				neg	pos					
245				3										
246		B											GGT	
247														
248														
249														
250										273				
251								neg	pos					
252													GGT	
253					VLR							H61 CTG	GGT	
254		A		tr				neg	pos				GGT	
255														
256				2									GGT	
257				2	LN			pos	neg			K13 GAC	GGT	
258														
259														
260														
261														
262														
263														
264				0										
265														
266		AB												

TABLE V. Range of In Vitro Data (Continued)

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
267	NI	LOH												
268														
269														
270	NI	AB			SN			neg	pos			K12	GCT	I
271		A											GGT	
272														
273								neg	pos					
274								neg	pos					
275				2	LN			pos	neg			K12	TGT	IIb
276														
277	NI	A		3										
278				4									GGT	
279														
280													GGT	
281					MN								GGT	
282														
283		A			MN								GGT	
284								neg	pos					
285														
286				2	SN			pos	pos				GGT	
287		AB						pos	pos					
288	LOH	LOH			SN								GGT	
289														
290				0,tr										
291				2				neg	pos				GGT	
292														
293														
294														
295				1										
296														
297	NI	A		4	MN			pos	neg			K12	TGT	
298														
299				3									GGT	
300				3										
301														
302	LOH							neg	pos					
303														
304				3										

A	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
305														
306								neg	pos					
307								mut	pos					
308														
309														
310														
311														
312				0				pos	neg					
313								neg	neg					
314								pos	neg				GGT	
315														
316														
317														
318								pos	neg					
319														
320								neg	pos					
321														
322														
323								pos	neg			N61 CGA	GGT	
324														
325		A												
326														
327								pos	neg					
328														
329														

TABLE V. Range of In Vitro Data (Continued)

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
1	DST	D3S4	D3S30	D3S3	DNF15S2	D3S32	D3S2	erbAB/H	erb AB/R	raf/R1	raf1/Bgl	raf/Taq	D3S18	D3S17
2														
3														
4														
5														
6														
7														
8														
9														
10														
11														
12		12	1		1	1	1	1		1			1	1
13	25.7	12	1		1	1	1	1		1			1	1
14														
15														
16														
17					1	2		1	1		1	1		
18					2	1		2	2		2	2		
19														
20														
21		12	1	1	12	2	12	1				12	12	12
22	34	12	1	1	12	2	12	1		1	2	12	12	12
23														
24				0	0		0							
25														
26		1	1	1	1	2	1	1		12			12	12
27	76	1	1	1	1	2	1	1		12	2	12	12	12
28														
29														
30														
31														
32														
33														
34		12	12	1	1	12	12	12		1			12	12
35		1	1	1	1	1	1	1		1			1	1
36														
37														
38		1	12	1	12	1	1	1		1			1	12

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
39	22.7	1	12	1	12	1	1	1		1			1	12
40														
41								1						
42														
43		12	1	1	1	1	12	1		1			1	1
44		12	1	1	1	1	12	1		1			1	1
45														
46														
47														
48		12	1	1	1	12	1	1			2		12	1
49		12	1	1	1	12	1	1		12	2	2	12	1
50														
51														
52	69.3				2	1		1		1	1	1		
53														
54														
55		12	1	1	12	2	1	2		1			1	12
56	35.3	12	1	1	12	2	1	2		1	1	1	1	12
57														
58														
59														
60								2						
61														
62		12	1	1	1	1	12	1		1			1	1
63		12	1	1	1	1	12	1		1			1	1
64														
65														
66														
67														
68														
69	54.3				12	2		12		12	12	12		
70														
71														
72														
73		1	1	1	12	12	1	12		12			1	12
74	7.3	1	1	1	12	12	1	12		12	12	0?	1	12
75														
76														

TABLE V. Range of In Vitro Data (Continued)

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
77														
78														
79														
80														
81														
82	52.3				2	2		2		1	1	0		
83	47				2	1		2		1	1	1		
84														
85														
86														
87														
88														
89														
90														
91														
92	82.7							1						
93														
94														
95														
96								1						
97														
98														
99	76.7				1	1		2		2	2	0?		
100					2	2		1		1	1	1		
101														
102	76.7				2	1		12?		1	1	1		
103	63													
104					1	2		2	1		2	2		
105					1	2		1		12	12	12		
106														
107														
108														
109														
110					2	2		1	1		2	1		
111	76				1	1		1		1	1	1		
112								1						
113	64							1						
114					1	1		1	1		2	2		

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
115		1	1	12	1	1	1	1		1			1	1
116		1	1	12	1	1	1	1		1			1	1
117		12	1	1	12	1	1	1		1			1	
118		1	1	1	1	1	1	1		1			1	
119														
120														
121					1	1		1	0		1	1		
122														
123														
124					1	1			1		2	1		
125														
126		12	1		2	2	1	1		1			1	1
127	6.7	12	1		2	2	1	1		1	1	1	1	1
128			12	1	1	1	1	1		1				
129	24.7		12	1	1	1	1	1		1				
130	68.7				1	2		1		2	2	2		
131	66				2	0		1		0	1	1		
132					2	2		1	12		2	1		
133					2	2		2	1		2	1		
134														
135														
136														
137					2	1		1	1		1	1		
138														
139														
140														
141					2	2		1	12		2	2		
142														
143														
144					1	1		12		1	1	1		
145														
146														
147														
148														
149		12	1	1	1	1	1	1		1			1	1
150		12	1	1	1	1	1	1		1			1	1
151														
152														

TABLE V. Range of In Vitro Data (Continued)

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
153					2	1		1	1		1	1		
154														
155					2	2		2	1		2	1		
156	13.3				1	2		2		1	2	2		
157		1	1	1	1	12	12	12		12			1	12
158		1	1	1	1	1	1	1		1			1	1
159		1	12	12	1	12	1	12		1			1	1
160		1	1	1	1	1	1	1		1			1	1
161		1	12	1	1	12	12	12		1			1	12
162		1	12	1	1	12	12	12		1			1	12
163														
164			12		12		12	1						
165			12		12	12	12	1		12	12	12		
166					1	2		1	12		1	1		
167	95.3				1	2		1		1	2	1		
168					1	2		1		1	2	1		
169														
170	30													
171			12	1	1		1	12						
172			1	1	1		1	1						
173														
174	32.7				2	2		1		1	2	1		
175		1	12	1	12	2	1	12		1			1	12
176		1	12	1	12	2	1	12		1	1	1	1	12
177														
178	65.3													
179														
180														
181	43.7				1	2		1		2	2	2		
182		1	1	1	12	2	12	1			1	1	1	12
183		1	1	1	2	2	1	1	1		1	1	1	1
184	74.7				2	1		12?		1	1	1		
185		12	12	1	12	12	12	12		1			1	12
186		1	1	1	2	1	1	2	1	1	2	2	1	1
187														
188	59.3				2	1		2		1	2	1		
189														
190														

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
191			1	1	12	2	1	1					1	
192			1	1	1	2	1	1	0		1	1	1	
193														
194					1	2		1		1	2	1		
195														
196														
197														
198														
199														
200														
201														
202														
203														
204														
205					12	1		12		12	12	12		
206														
207					1	1		2		1	1	1		
208														
209														
210														
211														
212														
213					1	1		2	1		1	1		
214														
215														
216														
217														
218														
219														
220														
221														
222														
223														
224														
225														
226														
227														
228														

TABLE V. Range of In Vitro Data (Continued)

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
229														
230														
231														
232														
233														
234														
235														
236														
237														
238														
239														
240														
241														
242														
243														
244														
245														
246														
247														
248														
249														
250														
251														
252														
253														
254														
255														
256														
257														
258														
259														
260														
261														
262														
263														
264														
265														
266														

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
267														
268														
269														
270														
271														
272														
273														
274														
275														
276														
277														
278														
279														
280														
281														
282														
283														
284														
285														
286														
287														
288														
289														
290														
291														
292														
293														
294														
295														
296														
297														
298														
299														
300														
301														
302														
303														
304														

TABLE V. Range of In Vitro Data (Continued)

A	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM
305														
306														
307														
308														
309														
310														
311														
312														
313														
314														
315														
316														
317														
318														
319														
320														
321														
322														
323														
324														
325														
326														
327														
328														
329														

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
1	YNZ22/Ba	c-myc amp	c-myc exp	n-myc amp	n-myc exp	l-myc amp	l-myc exp	3p abnormalities	3pN	3pA	Mode	Range
2												
3												
4												
5												
6												
7												
8												
9												
10												
11												
12												
13								normal	2		54	46-130
14								t(3p;14q)	3			
15		1	1	0	0	0	0	normal	2	0		
16												
17		0	0	1	1	0	0	normal	2	0		
18		1	1	0	0	0	0	del(3p)	2	1		
19												
20												
21												
22								normal	3		65	45-88
23												
24												
25												
26												
27								normal	1		42	34-83
28												
29												
30												
31								del(p13-p21)	2	1		
32												
33								del(p22-p23), del(	2		53	40-108
34												
35		0	0	0	0	0	1	del(p13-pter),del(	1	2		
36								iso(3p), t(3;4)(pte	0	1		
37												
38												

TABLE V. Range of In Vitro Data (Continued)

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
39								del(p25)	1		47	32-88
40												
41												
42												
43												
44								normal	3	0		
45												
46												
47								del(p14-p23), t(3p	1			
48												
49								t(3p;16q), t(3p;17	2			
50												
51												
52								inv(3p13)	0		54	51-59
53								del(p21)	2		57	43-60
54								del(p11-p24)	2	1		
55												
56								del(p14-p23), inv(3p)			70	63-76
57												
58												
59												
60		0	0	0	0	1	1	del(p12-p22)	1	1		
61												
62												
63												
64												
65								normal	2	1		
66												
67												
68								del(p22-p25), t(3;	1	2		
69												
70		1	1	0	0	0	0					
71												
72												
73												
74								none	2			
75												
76												

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
77												
78												
79												
80								normal	2	0		
81								t(3p14;6p11)	0			
82								del(p23), t(3p14;5	2		58	52-62
83								normal	2		54	48-113
84												
85								normal	2	0		
86												
87												
88												
89												
90												
91												
92								normal	2		75	66-176
93												
94												
95												
96												
97												
98												
99								t(3p14;11p15)	3		89	74-176
100								del(p14-p23), inv(	1		90	54-178
101												
102								t(3p13;5p15)	2		60	43-124
103												
104												
105								del(p14-pter)	2			
106												
107												
108		0	0	0	0	0	0					
109												
110												
111								del(p14-p23), t(3p	1			
112												
113								t(2p25;3p14),t(3p	2			
114												

TABLE V. Range of In Vitro Data (Continued)

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
115												
116												
117												
118												
119												
120												
121								t(1;3)del(3)(p14-p	2	1		
122												
123												
124								del(p13-p21), del(	1	3		
125												
126												
127								normal	2			
128												
129												
130								del(p13-pter)	1			
131												
132								t(2p,3p), t(3q,9q)	0	1		
133												
134												
135												
136												
137								t(2p,3q)	2	2		
138												
139												
140												
141								t(3q,17q)	2	1		
142												
143												
144												
145												
146												
147								normal	2	0		
148												
149												
150												
151												
152								del(p12-pter)	1	1		

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
153								del(p12-p23)	2	2		
154												
155												
156								normal	2			
157												
158												
159	12											
160	1							del(p13-p21)	1	2		
161												
162												
163												
164												
165												
166												
167												
168								del(p22-p24)	2	1		
169												
170												
171	12											
172	1							iso(3q)	1	1		
173												
174								none	2		54	43-66
175												
176								del(p14)	2		60	52-118
177												
178									1			
179												
180												
181												
182												
183												
184												
185	12											
186	2							normal	2	0		
187	1											
188	1											
189												
190												

TABLE V. Range of In Vitro Data (Continued)

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
191	12											
192	1											
193												
194												
195								none				
196											46	41-118
197												
198												
199	12											
200	1											
201												
202												
203												
204												
205												
206												
207												
208								del(p14-p23), del(	2		100	80-100
209												
210												
211												
212												
213												
214												
215												
216	1											
217	1											
218												
219												
220												
221												
222												
223												
224												
225												
226												
227								del(p21-pter)	2	1		
228												

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
229												
230												
231												
232												
233												
234												
235												
236												
237												
238								normal	2	0		
239												
240												
241												
242												
243												
244								del(p11-qter)	2	1		
245												
246												
247												
248												
249												
250												
251												
252												
253												
254								iso(3q)	1	1		
255												
256								del(p13-p21)	1	3		
257												
258												
259												
260								normal	1	0		
261												
262												
263												
264												
265												
266												

TABLE V. Range of In Vitro Data (Continued)

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
267												
268								t(1,3), t(3,7), t(3,1	0	5		
269												
270												
271												
272												
273												
274												
275												
276												
277												
278												
279												
280												
281												
282												
283												
284												
285												
286												
287												
288												
289												
290												
291												
292												
293												
294												
295												
296												
297												
298												
299												
300												
301												
302								normal	2	2		
303												
304												

A	AN	AO	AP	AQ	AR	AS	AT	AU	AV	AW	AX	AY
305												
306								iso(3q)	1	1		
307												
308												
309												
310												
311												
312												
313												
314												
315												
316												
317												
318												
319												
320												
321												
322												
323												
324												
325												
326												
327												
328												
329												